<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN"  "JATS-archivearticle1-3-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic" pub-type="epub">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">103332</article-id><article-id pub-id-type="doi">10.7554/eLife.103332</article-id><article-id pub-id-type="doi" specific-use="version">10.7554/eLife.103332.3</article-id><article-version article-version-type="publication-state">version of record</article-version><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Stem Cells and Regenerative Medicine</subject></subj-group></article-categories><title-group><article-title>Identification of a sub-population of synovial mesenchymal stem cells with enhanced treatment efficacy in a rat model of osteoarthritis</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Al-Jezani</surname><given-names>Nedaa</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Affan</surname><given-names>Asmaa</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Leonard</surname><given-names>Catherine</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Das</surname><given-names>Nabangshu</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Almeida</surname><given-names>Luiz Gustavo</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-8961-8883</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Young</surname><given-names>Daniel</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Masson</surname><given-names>Anand O</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Dufour</surname><given-names>Antoine</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Salo</surname><given-names>Paul</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-4005-9758</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Railton</surname><given-names>Pam</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Powell</surname><given-names>James N</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con11"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Krawetz</surname><given-names>Roman J</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-2576-4504</contrib-id><email>rkrawetz@ucalgary.ca</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund2"/><xref ref-type="fn" rid="con12"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03yjb2x39</institution-id><institution>McCaig Institute for Bone and Joint Health, University of Calgary</institution></institution-wrap><addr-line><named-content content-type="city">Calgary</named-content></addr-line><country>Canada</country></aff><aff id="aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03yjb2x39</institution-id><institution>University of Calgary, Biomedical Engineering Graduate Program</institution></institution-wrap><addr-line><named-content content-type="city">Calgary</named-content></addr-line><country>Canada</country></aff><aff id="aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03yjb2x39</institution-id><institution>Department of Physiology and Pharmacology, University of Calgary</institution></institution-wrap><addr-line><named-content content-type="city">Calgary</named-content></addr-line><country>Canada</country></aff><aff id="aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03yjb2x39</institution-id><institution>Department of Surgery, University of Calgary</institution></institution-wrap><addr-line><named-content content-type="city">Calgary</named-content></addr-line><country>Canada</country></aff><aff id="aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03yjb2x39</institution-id><institution>Department of Anatomy and Cell Biology, University of Calgary</institution></institution-wrap><addr-line><named-content content-type="city">Calgary</named-content></addr-line><country>Canada</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Radisic</surname><given-names>Milica</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03dbr7087</institution-id><institution>University of Toronto</institution></institution-wrap><country>Canada</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Cheah</surname><given-names>Kathryn Song Eng</given-names></name><role>Senior Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02zhqgq86</institution-id><institution>University of Hong Kong</institution></institution-wrap><country>Hong Kong</country></aff></contrib></contrib-group><pub-date publication-format="electronic" date-type="publication"><day>20</day><month>01</month><year>2026</year></pub-date><volume>14</volume><elocation-id>RP103332</elocation-id><history><date date-type="sent-for-review" iso-8601-date="2024-11-11"><day>11</day><month>11</month><year>2024</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint.</event-desc><date date-type="preprint" iso-8601-date="2024-11-10"><day>10</day><month>11</month><year>2024</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2024.11.10.622893"/></event><event><event-desc>This manuscript was published as a reviewed preprint.</event-desc><date date-type="reviewed-preprint" iso-8601-date="2025-02-11"><day>11</day><month>02</month><year>2025</year></date><self-uri content-type="reviewed-preprint" xlink:href="https://doi.org/10.7554/eLife.103332.1"/></event><event><event-desc>The reviewed preprint was revised.</event-desc><date date-type="reviewed-preprint" iso-8601-date="2025-12-18"><day>18</day><month>12</month><year>2025</year></date><self-uri content-type="reviewed-preprint" xlink:href="https://doi.org/10.7554/eLife.103332.2"/></event></pub-history><permissions><copyright-statement>© 2025, Al-Jezani et al</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>Al-Jezani et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-103332-v1.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-103332-figures-v1.pdf"/><abstract><p>Osteoarthritis (OA) is a painful, debilitating disease with no cure or treatments that can predictably stop/reverse its progression. Treatment is particularly difficult since articular cartilage lacks intrinsic repair capacity, despite mesenchymal stem cells (MSCs) being present in the joint with robust chondrogenic potential. While heterogeneity exists among MSC subtypes within human synovium, it remains unclear which populations can regenerate cartilage or impact OA progression. We clonally isolated MSCs from normal and OA patient synovium using indexed flow cytometry, then characterized them through differentiation assays and quantitative proteomics. MSC clones were transplanted into a xenograft rat OA model and evaluated by histology and immunofluorescence. We identified heterogeneity in putative MSCs within and between patient groups and their repair capacity in the rat model. However, traditional cell surface markers could not distinguish these subtypes, highlighting the need for single-cell level understanding. Using unbiased proteomics, we identified CD47 as a novel MSC marker. CD47<sup>Hi</sup> cells demonstrated robust treatment efficacy in the rat OA model and directly contributed to new articular cartilage formation. Characterizing MSC subtypes is essential for identifying candidates appropriate for clinical investigation and exploiting functional MSCs for cartilage regeneration strategies.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>stem cells</kwd><kwd>rodent OA model</kwd><kwd>human cells</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Rat</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01h531d29</institution-id><institution>Natural Sciences and Engineering Research Council of Canada</institution></institution-wrap></funding-source><award-id>RGPIN-2014-04586</award-id><principal-award-recipient><name><surname>Krawetz</surname><given-names>Roman J</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="ror">https://ror.org/000az4664</institution-id><institution>Canada Foundation for Innovation</institution></institution-wrap></funding-source><award-id>JELF</award-id><principal-award-recipient><name><surname>Krawetz</surname><given-names>Roman J</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution>Calgary Foundation</institution></institution-wrap></funding-source><award-id>Grace Glaum Professorship</award-id><principal-award-recipient><name><surname>Krawetz</surname><given-names>Roman J</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>CD47<sup>Hi</sup> synovial mesenchymal stem cells are identified as a functionally distinct sub-population that regenerates articular cartilage and reduces osteoarthritis severity in a preclinical joint injury model.</meta-value></custom-meta><custom-meta specific-use="meta-only"><meta-name>publishing-route</meta-name><meta-value>prc</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Osteoarthritis (OA) is a chronic joint disease that is characterized by progressive degeneration of the articular cartilage and results in structural changes throughout the joint, including deformity in the subchondral bone, loss of muscle tissue, and inflammation in the synovial membrane (<xref ref-type="bibr" rid="bib3">Arden et al., 2021</xref>; <xref ref-type="bibr" rid="bib19">Grandi and Bhutani, 2020</xref>; <xref ref-type="bibr" rid="bib45">Ni et al., 2020</xref>). These alterations to joint tissues ultimately lead to disability, which in turn results in a major socio-economic burden for impacted individuals and their respective healthcare systems (<xref ref-type="bibr" rid="bib16">Fellows et al., 2016</xref>; <xref ref-type="bibr" rid="bib48">Palazzo et al., 2014</xref>; <xref ref-type="bibr" rid="bib54">Salmon et al., 2016</xref>). Developing a therapy for OA is particularly challenging for multiple reasons, including the multifactorial and elusive nature of the disease (<xref ref-type="bibr" rid="bib20">Hafsi et al., 2019</xref>; <xref ref-type="bibr" rid="bib44">Mora et al., 2018</xref>); and inherent properties of the cartilage (absence of blood vessels and nerves), which results in limited endogenous repair capacity (<xref ref-type="bibr" rid="bib16">Fellows et al., 2016</xref>; <xref ref-type="bibr" rid="bib17">Fernandes et al., 2018</xref>). All current approved treatments for OA patients focus on symptoms, such as pain management but fail to address the core issue of OA; the degeneration of the cartilage and related structural changes within the joint. In view of these limitations in treatment options, researchers have extensively investigated the use of MSCs (also referred to as mesenchymal progenitor/stromal cells) (<xref ref-type="bibr" rid="bib14">Dimarino et al., 2013</xref>) as an alternative treatment modality since they are hypothesized to reduce pain and inflammation through immunomodulatory abilities (<xref ref-type="bibr" rid="bib36">Lee et al., 2015</xref>), while also potentially being able to induce the repair/regeneration of cartilage through direct differentiation into chondrocytes (<xref ref-type="bibr" rid="bib38">Mak et al., 2016</xref>) and/or the release of trophic factors to stimulate indirect repair (<xref ref-type="bibr" rid="bib58">Soland et al., 2013</xref>). MSCs have garnered significant attention over the past two decades, not only because these self-renewing cells possess multi-lineage differentiation capacity but also because these cells have the ability to influence their microenvironment through multiple means (<xref ref-type="bibr" rid="bib13">de Witte et al., 2018</xref>; <xref ref-type="bibr" rid="bib28">Kim et al., 2018</xref>). MSCs have been identified within nearly every mesodermally derived tissue, yet synovial-derived MSCs have been shown to have superior chondrogenic and self-renewing capacity when compared to MSCs derived from a variety of tissues, such as bone marrow and adipose tissue (<xref ref-type="bibr" rid="bib10">De Bari et al., 2001</xref>; <xref ref-type="bibr" rid="bib18">Futami et al., 2012</xref>; <xref ref-type="bibr" rid="bib46">Nishimura et al., 1999</xref>; <xref ref-type="bibr" rid="bib53">Sakaguchi et al., 2005</xref>). Although MSC-based therapies in numerous pre-clinical studies have shown promising results for the treatment of cartilage injury and/or OA (<xref ref-type="bibr" rid="bib26">Jia et al., 2018</xref>; <xref ref-type="bibr" rid="bib35">Krawetz et al., 2023</xref>; <xref ref-type="bibr" rid="bib38">Mak et al., 2016</xref>; <xref ref-type="bibr" rid="bib55">Satué et al., 2019</xref>), outcomes from clinical trials have largely been disappointing, with some studies demonstrating that MSC therapy offers little to no advantage over conventional surgical treatments, such as microfracture or corticosteroid injection (<xref ref-type="bibr" rid="bib31">Koh et al., 2016</xref>; <xref ref-type="bibr" rid="bib42">Mautner et al., 2023</xref>).</p><p>In the vast majority of these pre-clinical and clinical studies, cells are isolated and defined as MSCs based on the guidelines proposed by the International Society for Cellular Therapy (ISCT) (<xref ref-type="bibr" rid="bib15">Dominici et al., 2006</xref>). The minimum criteria that must be met include adherence to plastic cell culture-ware, multipotent differentiation capacity (typically bone, cartilage, and fat), and the expression (and/or lack of expression) of a panel of cell surface markers. Unfortunately, even when satisfying these criteria, MSC phenotypic heterogeneity has been observed in animal and human model systems across multiple tissue types (<xref ref-type="bibr" rid="bib50">Phinney, 2012</xref>; <xref ref-type="bibr" rid="bib52">Russell et al., 2010</xref>; <xref ref-type="bibr" rid="bib61">Zhou et al., 2019</xref>). In a previous study, we found significant MSC heterogeneity in clonal populations of cells derived from hip synovium even when cell populations expressed similar combinations of cell surface markers (<xref ref-type="bibr" rid="bib1">Affan et al., 2019</xref>). Therefore, there is a concern that this heterogeneity might negatively impact the capacity of MSCs to demonstrate clinical efficacy both within cohorts and across studies if we can’t be sure the same cell type (or subtype) is being isolated and delivered back to patients. Furthermore, since most of the published human MSC data comes from cultured cells, it is also possible that a strong selection bias is induced by the in vitro conditions which modify the properties and populations (subtypes) of the cultured MSCs. Emerging research supports the concept that DPP4<sup>+</sup> (also marked by PI16 and CD34) synovial cells function as multipotent stromal progenitors. In postnatal mice, DPP4<sup>+</sup> mesenchymal progenitor cells (MPCs) give rise to Prg4<sup>+</sup> synovial lining fibroblasts (SLFs) and adipocytes, contributing to normal joint development and synovial homeostasis, with activation and expansion after OA injury. Single-cell transcriptomic atlases further identify PI16<sup>+</sup> fibroblasts in perivascular niches as latent reservoirs capable of differentiating into specialized synovial lineages following injury. Together, findings across human and mouse OA (<xref ref-type="bibr" rid="bib7">Collins et al., 2023</xref>; <xref ref-type="bibr" rid="bib30">Knights et al., 2023</xref>; <xref ref-type="bibr" rid="bib37">Li et al., 2024</xref>; <xref ref-type="bibr" rid="bib49">Peters et al., 2025</xref>; <xref ref-type="bibr" rid="bib59">Tang et al., 2024</xref>) models underscore the progenitor role of these universal fibroblasts and highlight the need for a better understanding of the subtypes of MSCs within the joint environment (by identification of the markers that correlate with functional properties advantageous for therapy) might allow for the isolation of specific populations which are best suited for cartilage regeneration applications.</p><p>Therefore, this study employed a unique approach to examine the cell phenotype of clonally derived synovial MSCs obtained directly from synovial tissue (without an initial cell culture step). We have: (1) characterized the cell surface marker expression of clonal populations in situ vs. in vitro to determine the robustness of ISCT-recommended markers; (2) correlated the marker expression with multipotent differentiation capacity; (3) determined if the cell surface marker expression could predict MSC differentiation potential; (4) examined the ability of different clonal populations to treat OA in a preclinical rat model; and (5) characterized the global proteome expression pattern of MSCs isolated from normal vs. OA joints and also MSCs vs. non-MSCs derived sub-populations.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>Clonal MSC derivation</title><p>In this study, synovial biopsies were collected from 15 patients undergoing knee orthopedic procedures and 18 normal cadaveric donors (<xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>). From the normal synovium, 228 clonal cell lines were generated, while 259 clonal lines were derived from osteoarthritic (OA) synovium (<xref ref-type="supplementary-material" rid="supp2">Supplementary file 2</xref>). Out of these, 29 clones from the normal synovium and 37 from the OA synovium exhibited the self-renewal potential required to expand to a population size suitable for further analysis, such as differentiation and flow cytometry (<xref ref-type="supplementary-material" rid="supp3">Supplementary file 3</xref>).</p><p>To complete all differentiation and flow cytometry analyses (including replicates), each clonally derived synovial MSC line needed to undergo approximately 19 population doublings. However, most clonal cell lines lacked the self-renewal capacity necessary to meet the study’s characterization criteria (<xref ref-type="supplementary-material" rid="supp3">Supplementary file 3</xref>).</p><p>A negative correlation was observed between donor age and the population doublings of clones derived from that donor (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>). This relationship was more pronounced in OA patients compared to normal donors. No correlation was found between sex and population doublings (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>).</p></sec><sec id="s2-2"><title>Cell surface marker expression in situ vs. in vitro</title><p>The data presented is a representative example from one normal and one OA patient (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2</xref>), while the collective results are summarized in <xref ref-type="supplementary-material" rid="supp4 supp5">Supplementary files 4 and 5</xref>. Cell surface marker profiles were compared in situ (pre-culture, indexed cell sorting was used to record cell surface profiles) and in vitro (post-culture). Flow cytometry analysis revealed that cell surface expression of the cloned cells (isolated from both OA and Normal) became altered by exposure to the cultural microenvironment (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2A, B</xref>). Specifically, four clones were obtained from a single normal individual. Clone 1 was initially positive for CD90, CD44, and CD73 in situ and negative for CD105 and CD271, yet this clone gained the expression of CD105 in vitro. Clones 2, 3, and 4 shared similar expression in situ (expressing CD44 and CD73 while lacking the expression of CD90, CD105, and CD271). Similar to clone 1, these clones acquired the expression of CD105 as well as CD90 (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2A</xref>). Clones attained from a single OA individual show a similar pattern. Clones 1 and 2 were positive for CD44 and negative for CD90, CD73, CD105, and CD271 in situ and gained the expression of CD90, CD73, and CD105 in vitro. Clone 3 was CD44 and CD73 positive in situ and gained expression of CD90 and CD105 in vitro. Clone 4 expressed CD90 and CD73 in situ and gained expression of CD44 and CD105 in vitro.</p><p>Collectively, the common trend observed in the clones presented and those from the entire cohort was that despite a heterogeneous cell surface marker expression profile in situ, the marker profile aligned in vitro with nearly all clones (normal and OA) expressing CD90, CD44, CD73, and CD105 (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2</xref>, <xref ref-type="supplementary-material" rid="supp4 supp5">Supplementary files 4 and 5</xref>). Since this experiment was performed clonally, we can conclusively state that the individual cells self-regulated their unique cell surface profiles to a common profile once expanded in culture. Overall, this demonstrates a convergent selection bias towards the traditional cell surface marker profile expressed by MSCs.</p></sec><sec id="s2-3"><title>Multipotential differentiation assessment</title><p>Aside from cell surface marker expression, a hallmark of ‘stemness’ includes self-renewal ability and multipotent differentiation capacity; therefore, clones were identified as MSCs if they demonstrated differentiation into bone, cartilage, and fat in vitro. The data presented is a representative example from <underline>one normal</underline> and <underline>one OA</underline> patient (<xref ref-type="fig" rid="fig1">Figure 1</xref>), while the collective results are summarized in <xref ref-type="supplementary-material" rid="supp4 supp5">Supplementary files 4 and 5</xref>. Based on histological analysis, normal clones 1 and 2 stained positive for Alizarin Red, Safranin O, and Oil Red O when induced to differentiate into osteoblasts, chondrocytes, and adipocytes (<xref ref-type="fig" rid="fig1">Figure 1A</xref>). When qPCR analysis was performed, clone 1 expressed <italic>Sp7</italic> (osteogenic), <italic>Col2A1,</italic> and <italic>Sox9</italic> (chondrogenic), but lacked the expression of <italic>Adiponectin</italic> (adipogenic) (<xref ref-type="fig" rid="fig1">Figure 1B–C</xref>). Clone 2 upregulated all differentiation markers (<xref ref-type="fig" rid="fig1">Figure 1B–C</xref>). Clones 3 and 4 lacked Alizarin Red staining but stained positive for both Safranin O and Oil Red (<xref ref-type="fig" rid="fig1">Figure 1A</xref>). Clone 3 expressed <italic>Sp7</italic>, <italic>Col2a,</italic> and <italic>Adiponectin</italic> (<xref ref-type="fig" rid="fig1">Figure 1B–C</xref>) while clone 4 only expressed <italic>Adiponectin</italic> (<xref ref-type="fig" rid="fig1">Figure 1B–C</xref>).</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>In vitro differentiation potential of clones derived from normal individuals and patients with osteoarthritis (OA).</title><p>Representative histological staining of Alizarin Red, Safranin O, and Oil Red O from four normal (<bold>A</bold>) and four OA clones (<bold>E</bold>). Quantitative PCR (QPCR) data (n=3 biological replicates and n=3 technical replicates, each point is the mean of the technical replicates) is presented for each of the clones for osteogenic (<bold>B, F</bold>), chondrogenic (<bold>C, G</bold>), and adipogenic (<bold>D, H</bold>) markers. Signifiance determined by t-Test. *<italic>p</italic>&lt;0.05, **<italic>p</italic>&lt;0.01. Scale bars equal 200 µm.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-103332-fig1-v1.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title>Association between population doublings, sex, and age.</title><p>A significant negative association was observed between age and population doublings in clones derived from normal and osteoarthritis (OA) synovium. There was no association between sex and population doubling determined by Spearman Correlation, <italic>p</italic>&lt;0.05.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-103332-fig1-figsupp1-v1.tif"/></fig><fig id="fig1s2" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 2.</label><caption><title>In situ and in vitro cell surface protein expression on clones derived from normal individuals and patients with osteoarthritis (OA).</title><p>Representative histograms from 4 clones from normal (<bold>A</bold>) and OA (<bold>B</bold>) synovium are shown. The in situ expression of each CD marker is represented by the vertical dashed black bar. The in vitro expression of each marker in the clonal-derived cell population is represented by the red histogram. The isotype/negative control for each CD marker is represented by the blue histogram.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-103332-fig1-figsupp2-v1.tif"/></fig><fig id="fig1s3" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 3.</label><caption><title>Overview of the experimental design employed in the current study.</title></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-103332-fig1-figsupp3-v1.tif"/></fig></fig-group><p>Similar patterns were observed in the clones derived from OA patients. Clone 1, when induced to osteogenesis, chondrogenesis, and adipogenesis, was positive for Alizarin Red, Safranin O, and Oil Red (<xref ref-type="fig" rid="fig1">Figure 1E</xref>) and expressed <italic>Sp7</italic>, <italic>Runx2</italic>, <italic>Col2a1,</italic> and <italic>Adiponectin</italic> (<xref ref-type="fig" rid="fig1">Figure 1F–G</xref>). Clone 2 stained positive for Alizarin Red, Safranin O, Oil Red O, and expressed osteogenic and chondrogenic markers but lacked the expression of <italic>Adiponectin</italic> marker (<xref ref-type="fig" rid="fig1">Figure 1F–G</xref>). Clones 3 and 4 were negative for Alizarin Red but stained positive for Safranin O and Oil Red O (<xref ref-type="fig" rid="fig1">Figure 1E</xref>), but both clones expressed osteogenic markers (<xref ref-type="fig" rid="fig1">Figure 1F</xref>). Clone 3 lacked the chondrogenic markers, clone 4 displayed up-regulation of Sox9 (<xref ref-type="fig" rid="fig1">Figure 1G</xref>). Clone 3 expressed <italic>Adiponectin,</italic> while clone 4 did not (<xref ref-type="fig" rid="fig1">Figure 1H</xref>).</p><p>Based on ISCT criteria, for a clone to be considered as an MSC, it needed to demonstrate multipotent differentiation capacity in osteoblasts, chondrocytes and adipocytes (<xref ref-type="bibr" rid="bib15">Dominici et al., 2006</xref>). Since we observed some level of disagreement between histological and molecular analysis of differentiation, we decided that each clone had to demonstrate positive histological staining with positive marker gene expression to be considered conclusively differentiated into a specific lineage. Therefore, for the eight clones presented in <xref ref-type="fig" rid="fig1">Figure 1</xref>, only normal clones 1, 2, and OA clones 1, 2 were defined as MSCs. <xref ref-type="supplementary-material" rid="supp4 supp5">Supplementary files 4 and 5</xref> summarize all data collected from both normal and OA knee joints, respectively. When the differentiation capacity of the clones was compared to the cells in situ (pre-culture) cell surface marker expression, the most frequent marker phenotype of cells that met the minimal criteria for MSCs (in situ) was CD90<sup>+</sup>CD44<sup>+</sup>CD73<sup>+</sup>.</p></sec><sec id="s2-4"><title>Cell surface profile validation</title><p>To determine if CD90<sup>+</sup>CD44<sup>+</sup>CD73<sup>+</sup> expression defines MSC populations in situ, synovial membrane samples from a new cohort of patients (n=4 normal, n=4 OA) were obtained. In this experiment, we directly compared between cells that were triple positive for CD90<sup>+</sup>CD44<sup>+</sup>CD73<sup>+</sup> (live, CD68<sup>-</sup>) vs. all live CD68<sup>-</sup> cells that did not have this exact expression profile. Interestingly, cells enriched for CD90<sup>+</sup>CD44<sup>+</sup>CD73<sup>+</sup> expression did not guarantee multipotent differentiation potential (summarized in <xref ref-type="supplementary-material" rid="supp6">Supplementary file 6</xref>). On the contrary, samples that did not contain the CD90<sup>+</sup>CD44<sup>+</sup>CD73<sup>+</sup> population still retained differentiation potential in OA and normal synovium meeting the MSC criteria. Furthermore, after culture in vitro, all lines expressed all MSC markers except CD271. Based on this experiment, an expression profile of CD90<sup>+</sup>CD44<sup>+</sup>CD73<sup>+</sup> on cells directly isolated from synovial membrane does not presumptively identify MSCs.</p></sec><sec id="s2-5"><title>In vivo functional assessment</title><p>It was next decided to investigate if there was a functional difference between MSC vs. non-MSC clonally derived populations when injected into the knees of rats with surgically induced OA. DMM surgery was performed on the left knee of Lewis rats and 1 week post-DMM surgery, rats were either injected with clones classified as MSCs or non-MSCs (from both normal and OA synovium). Histological sections from control (sham-injured) and injured (treated with saline) rats were compared to rats that had been injured and injected with either MSC or non-MSC clones (<xref ref-type="fig" rid="fig2">Figure 2</xref>). Knees that received sham DMM appeared to be morphologically normal (<xref ref-type="fig" rid="fig2">Figure 2A</xref>), while knees that underwent DMM and received saline showed proteoglycan loss, areas of cartilage loss, and osteophyte formation (<xref ref-type="fig" rid="fig2">Figure 2B</xref>). DMM knees injected with MSCs showed some areas of reduced proteoglycan staining and surface fibrillation but did not present with areas of cartilage loss (<xref ref-type="fig" rid="fig2">Figure 2C</xref>). Injured knees that received non-MSCs showed proteoglycan loss, areas of synovial inflammation, surface fibrillation, and areas of cartilage loss (<xref ref-type="fig" rid="fig2">Figure 2D</xref>). Osteoarthritis Research Society International (OARSI) histological scoring and Krenn scoring were undertaken to quantify OA severity and synovial inflammation, respectively. These scores demonstrated that rats receiving MSCs had a significantly lower OARSI and Krenn score vs. rats injected with non-MSCs post-DMM surgery (<xref ref-type="fig" rid="fig2">Figure 2E</xref>, <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref>). These findings suggested that intra-articular injection of MSCs either inhibited degeneration and/or promoted regeneration to reduce the severity of OA, while the non-MSCs lacked this functional ability.</p><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>Osteoarthritis (OA) scoring with and without cell injection in a rat DMM model.</title><p>Representative images of rats with sham surgery (<bold>A, A’</bold>), DMM injury with injection of saline (<bold>B, B’</bold>), DMM injury with injection of mesenchymal stem cells (MSCs) (<bold>C, C’</bold>) or non-MSCs (<bold>D, D’</bold>). The Osteoarthritis Research Society International (OARSI) and Krenn scoring was quantified in each group (<bold>E</bold>). Scale bars equal 200 µm in A, B, C, D and 20 µm in A’, B’, C’, D’. *<italic>p</italic>&lt;0.05. Sample size as follows: control (sham) n=6, DMM (saline injected) n=6, DMM (MSC injected) n=3 rats per cell line, eight cell lines used (normal MSC x2 and non-MSC x2, OA MSC x2 and non-MSC x2). Normal and OA MSC groups and non-MSC groups added together. Signifiance determined by 2 way ANOVA. <italic>p</italic>&lt;0.05.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-103332-fig2-v1.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 1.</label><caption><title>Safranin O staining sections of rat synovium with or without cell delivery.</title><p>Representative images of synovium tissue from all four treatment groups (<bold>A–D</bold>). The summed Krenn score is shown along with the individual categories, including synovial lining, cellular density, and infiltration (<bold>E</bold>). Scale bars equal 40 µm. Signifiance determined by 1 way ANOVA. <italic>p</italic>&lt;0.05.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-103332-fig2-figsupp1-v1.tif"/></fig></fig-group><p>To examine whether the transplanted cell populations were capable of directly contributing to articular cartilage regeneration in vivo, the clones were virally labeled with TdTomato (to track their localization within the rat tissue). TdTomato<sup>+</sup> MSC clones (from normal and OA patients) were observed within the articular cartilage (<xref ref-type="fig" rid="fig3">Figure 3G, H, M and N</xref>) while TdTomato<sup>+</sup> non-MSC clones (from normal and OA patients) were not observed with cartilage tissue (<xref ref-type="fig" rid="fig3">Figure 3J, K, P and Q</xref>). In uninjured rats (<xref ref-type="fig" rid="fig3">Figure 3A and B</xref>) or injured rats injected with saline alone (<xref ref-type="fig" rid="fig3">Figure 3A and B</xref>), no TdTomato signal was detected.</p><fig-group><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>Exogenous cell contribution to cartilage repair in a rat DMM model.</title><p>Representative images of rats with sham surgery (<bold>A</bold>) without cell injection (no TdTomato – B) and endogenous PRG4/Lubricin staining (<bold>C</bold>). In rats injected with saline (<bold>D</bold>), no TdTomato (<bold>E</bold>) and disrupted PRG4/Lubricin (<bold>F</bold>) staining was observed. When normal (<bold>G</bold>) or osteoarthritis (OA) (<bold>M</bold>), mesenchymal stem cells (MSCs) were injected into injured rats, TdTomato expression (H.N) was observed. When normal (<bold>J</bold>) or OA (<bold>P</bold>) non-MSCs were injected, no TdTomato (<bold>K, Q</bold>) and disrupted PRG4/Lubricin (<bold>L, R</bold>) staining was observed. Scale bars equal 30 µm. Tissue cytometry was employed to quantify the number of tdTomato-positive, PRG4-positive, and double-positive cells within the articular cartilage (<bold>S</bold>). Signifiance determined by 2 way ANOVA. *<italic>p</italic>&lt;0.05, **<italic>p</italic>&lt;0.01. *=p&lt;0.05, N.S.=not significant . Sample size as follows: control (sham) n=6, DMM (saline injected) n=6, DMM (MSC injected) n=3 rats per cell line, eight cell lines used (normal MSC x2 and non-MSC x2, OA MSC x2 and non-MSC x2).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-103332-fig3-v1.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 1.</label><caption><title>Representative tissue cytometry gates.</title><p>Examples of gating strategy for each marker (DAPI, tdTomato, PRG4, tdTomato plus PRG4) in each experimental group.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-103332-fig3-figsupp1-v1.tif"/></fig><fig id="fig3s2" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 2.</label><caption><title>Mesenchymal stem cells (MSCs) within the cartilage produce collagen 2.</title><p>Representative images of a rat with DMM surgery (<bold>A</bold>) with MSC injection (TdTomato – B) and collagen 2 staining (<bold>C</bold>). Scale bars equal 20 µm.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-103332-fig3-figsupp2-v1.tif"/></fig></fig-group><p>To determine if the transplanted human cells generated functional articular chondrocytes, Lubricin/PRG4 staining was undertaken, since this protein is produced by chondrocytes and is essential to joint homeostasis in part by lubricating the articular surfaces (<xref ref-type="bibr" rid="bib8">Das et al., 2019</xref>; <xref ref-type="bibr" rid="bib23">Iqbal et al., 2016</xref>). In control (sham) joints, lubricin staining is primarily confined to the superficial zone of the cartilage resulting in a continuous layer of expression (<xref ref-type="fig" rid="fig3">Figure 3A and C</xref>). In DMM joints injected with saline, this protective layer of PRG4 staining is disrupted (<xref ref-type="fig" rid="fig3">Figure 3D and F</xref>). When MSCs (from normal or OA synovium) were injected into DMM joints, some level of restoration of the PRG4 protective layer was observed (<xref ref-type="fig" rid="fig3">Figure 3G, I, M and O</xref>). Interestingly, it was observed that normal MSC clones throughout the cartilage produced PRG4 (<xref ref-type="fig" rid="fig3">Figure 3G and I</xref>), while this was not observed with OA MSC clones (<xref ref-type="fig" rid="fig3">Figure 3M and O</xref>). In DMM joints injected with non-MSC clones (normal of OA), the PRG4 protective layer was disrupted (<xref ref-type="fig" rid="fig3">Figure 3J, K, P and R</xref>), similar to saline-injected joints (<xref ref-type="fig" rid="fig3">Figure 3D and F</xref>). A tissue cytometry approach (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1</xref>) was used to quantify the number of tdTomato, PRG4, and tdTomato with PRG4 expressing cells in the articular cartilage (<xref ref-type="fig" rid="fig3">Figure 3S</xref>). Overall, there was a significant increase in tdTomato and PRG4-expressing cells within the cartilage post-MSC treatment (regardless of being derived from normal/OA synovium); yet more tdTomato and PRG4-expressing cells were observed in joints treated with MSCs derived from normal vs. OA synovium. Furthermore, we also observed that while transplanted normal MSCs took on a PRG4-positive phenotype, MSCs from OA synovium did not. Non-MSCs, regardless of patient population, did not engraft into the articular cartilage nor take on a PRG4 positive phenotype (<xref ref-type="fig" rid="fig3">Figure 3S</xref>).</p><p>To determine if the MSC clones were regenerating/maintaining the articular cartilage in DMM joints, collagen 2 staining was undertaken. Collagen 2 staining was found within the articular cartilage of DMM joints and colocalized with TdTomato expression (<xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2</xref>). Taken together, these outcomes suggest that intra-articular injection of MSCs (normal or OA) resulted in the regeneration of articular cartilage in comparison with the intra-articular injection of non-MSCs that had no beneficial effect on the articular cartilage.</p></sec><sec id="s2-6"><title>Localization of non-MSC clones within the joint</title><p>Since non-MSC clones were not observed within the articular cartilage of the rats, the synovial tissue was examined (<xref ref-type="fig" rid="fig4">Figure 4</xref>). Few MSCs (normal and OA – normal clone shown as a representative example) were found within the synovium or adjacent tissue (<xref ref-type="fig" rid="fig4">Figure 4A</xref>), while many non-MSCs (normal and OA – normal clone – same patient as MSC clone, shown as a representative example) were observed throughout the synovium in both the intimal and subintimal layers (<xref ref-type="fig" rid="fig4">Figure 4B</xref>). To determine what role the cells were playing in the micro-environment, CCL2 staining was performed. CCL2 is a pro-inflammatory chemokine which recruits circulating monocytes from the blood to infiltrate tissue during inflammatory processes <xref ref-type="bibr" rid="bib12">Deshmane et al., 2009</xref>; is involved in OA pain and pathogenesis (<xref ref-type="bibr" rid="bib24">Jablonski et al., 2019</xref>; <xref ref-type="bibr" rid="bib43">Miller et al., 2012</xref>; <xref ref-type="bibr" rid="bib51">Raghu et al., 2017</xref>). We have demonstrated that CCL2 is expressed in OA MSCs and regulates their behaviour (<xref ref-type="bibr" rid="bib22">Harris et al., 2013</xref>). Although CCL2 staining did co-localize with tdTomato (MSCs), it was minimal (<xref ref-type="fig" rid="fig4">Figure 4A</xref>). CCL2 staining was also observed in the intimal layer but was independent of tdTomato expression (<xref ref-type="fig" rid="fig4">Figure 4A</xref>). This was in contrast to CCL2 staining when non-MSCs were injected into joints (<xref ref-type="fig" rid="fig4">Figure 4B</xref>). In non-MSC-injected joints, CCL2 staining was observed throughout the synovium and was highly co-localized with TdTomato expression (<xref ref-type="fig" rid="fig4">Figure 4B</xref>). Furthermore, since CCL2 is a secreted protein, it was interesting to observe that CCL2 staining appeared to diffuse out from the tdTomato<sup>+</sup> non-MSC clones (<xref ref-type="fig" rid="fig4">Figure 4B</xref>). When the number of CCL2-positive cells and the level of CCL2 staining (mean fluorescent intensity – MFI) was quantified, it was found that significantly more CCL2-positive cells and expression was detected in the synovium of rats injected with non-MSCs (normal or OA) (<xref ref-type="fig" rid="fig4">Figure 4C</xref>).</p><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>Contribution of transplanted cells to inflammatory signaling.</title><p>Representative images of mesenchymal stem cells (MSCs) (<bold>A</bold>) and non-MSCs (<bold>B</bold>) in the synovium of rats post-DMM. In rats injected with MSCs, only minimal CCL2 (<bold>A”</bold>) expression is observed and/or colocalized with tdTomato staining (<bold>A’</bold>). In rats injected with non-MSCs, intense CCL2 staining (<bold>B”</bold>) was observed that colocalized with tdTomato staining (<bold>B’</bold>). This was quantified using tissue cytometry (<bold>C</bold>). In rats injected with MSCs, little Ki67 staining was observed in the cartilage (<bold>D-D”</bold>). In rats injected with non-MSCs, nearly every transplanted cell in the synovium was also positive for Ki67 (<bold>E-E”</bold>). This was quantified using tissue cytometry (<bold>F</bold>). Signifiance determined by t-Test. <italic>p</italic>&lt;0.05. Scale bars equal 75 µm (A-B), 30 µm (<bold>D-E</bold>).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-103332-fig4-v1.tif"/></fig><p>In a previous study, we demonstrated that CCL2 acted upon MSCs by increasing their proliferative ability (<xref ref-type="bibr" rid="bib22">Harris et al., 2013</xref>). Therefore, we decided to examine MSC/non-MSC proliferation in the joint (synovium and cartilage) through Ki67 staining (<xref ref-type="fig" rid="fig4">Figure 4D–F</xref>). Within the articular cartilage, transplanted MSCs (normal or OA) demonstrated little to no Ki67 staining, indicating minimal cell proliferation (<xref ref-type="fig" rid="fig4">Figure 4D</xref>). Since non-MSC clones were not observed in the articular cartilage, no Ki67 staining was observed. In the synovium, MSC clones (normal or OA) demonstrated minimal positive Ki67 staining, while non-MSC clones demonstrated robust staining (<xref ref-type="fig" rid="fig4">Figure 4D</xref>). However, it is important to remember that significantly fewer MSCs were observed within the synovial tissue (<xref ref-type="fig" rid="fig4">Figure 4G</xref>), yet these cells were proliferative.</p></sec><sec id="s2-7"><title>Proteomics analysis of clonal populations</title><p>Since a clear difference was observed between in vitro and in vivo functionality/behaviour in the two different populations of synovial cells, a quantitative shotgun proteomics analysis was undertaken to understand the proteomic differences between the subtypes (<xref ref-type="fig" rid="fig5">Figure 5A</xref>). Several differentially expressed proteins were identified between the subtypes (<xref ref-type="supplementary-material" rid="supp7">Supplementary file 7</xref>, <xref ref-type="fig" rid="fig5">Figure 5B</xref>). Using Metascape (<xref ref-type="fig" rid="fig5">Figure 5C</xref>) and STRING-db (<xref ref-type="fig" rid="fig5">Figure 5D</xref>), analyses were undertaken on the proteins differentially regulated in MSCs, and several pathways were differentially enriched. An aspect of this proteomic workflow that was interesting was that the MSC subtype was enriched for CD47, ITGA5, and DPP4 expression. While ITGA5 and DPP4 have already been implicated in fibroblast and progenitor function, CD47 has been traditionally thought of as a signal to immune/macrophages that blocks their phagocytosis of these CD47-expressing cells. In terms of MSC expression of CD47, this molecule has been shown to enhance homing and immunomodulatory ability of the cells. Therefore, we characterized freshly isolated synovial samples from normal (n=3) and OA (n=3) joints for CD90<sup>+</sup>CD73<sup>+</sup>CD44<sup>+</sup> cells and examined what percentage of this population expressed CD47.</p><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>Proteomics analysis of mesenchymal stem cell (MSC) vs. non-MSC populations.</title><p>Schematic representation of the quantitative shotgun proteomics workflow (<bold>A</bold>). Volcano plot demonstrating the distribution of statistically changing proteins identified in MSCs (red) and Non-MSCs (blue) (<bold>C</bold>). Metascape analysis and heatmap showing pathways regulated by differentially expressed proteins in MSCs vs. non-MSCs (<bold>D</bold>). STRING-db analysis of protein-protein interaction networks with elevated proteins in MSCs (<bold>D</bold>).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-103332-fig5-v1.tif"/></fig></sec><sec id="s2-8"><title>CD47 as a marker of human synovial cells with in vivo chondrogenic potential</title><p>Synovial biopsies were recovered from an additional n=3 normal and n=3 OA knee joints and the CD90<sup>+</sup>CD73<sup>+</sup>CD44<sup>+</sup> population was identified (<xref ref-type="fig" rid="fig6">Figure 6A</xref>). This population of cells was further interrogated for the expression of CD47, and it was found that all CD73<sup>+</sup>CD44<sup>+</sup> double-positive cells expressed CD47, but there was also a CD47<sup>Hi</sup> population (<xref ref-type="fig" rid="fig6">Figure 6B and C</xref>) in both normal and OA synovium. The CD47<sup>Hi</sup> and CD47<sup>Lo</sup> sub-populations were both isolated by FACS and we further examined the immunophenotype of the cells. Specifically, we assayed if these CD47<sup>Hi</sup> and CD47<sup>Lo</sup> sub-populations expressed ITGA5 and/or DPP4/CD26 as these markers have previously been associated with stromal progenitors and shown to play a role in the progression of arthritis (<xref ref-type="bibr" rid="bib60">Zheng et al., 2025</xref>). The CD47<sup>Hi</sup> sub-population from normal and OA synovium expressed both ITGA5 and DPP4/CD26, whereas the CD47<sup>Lo</sup> sub-population was largely negative for both markers (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1</xref>). To further understand if there were any functional differences between sub-populations, we differentiated the cells into chondrocytes using standard pellet culture. Both CD47<sup>Hi</sup> and CD47<sup>Lo</sup> sub-populations produced pellets that stained positive for Alcian blue (<xref ref-type="fig" rid="fig6">Figure 6B and D</xref>); however, the CD47<sup>Hi</sup> cells appeared to have more instances of staining. Therefore, we quantified the GAG content and found that CD47<sup>Hi</sup> cells produced more GAGs than CD47<sup>Lo</sup> cells, regardless of if they were isolated from normal of OA synovium (<xref ref-type="fig" rid="fig6">Figure 6E</xref>). Collagen 2 staining of the pellets showed a similar trend in where more pronounced Col2 staining was observed in pellets derived from CD47<sup>Hi</sup> cells (<xref ref-type="fig" rid="fig6">Figure 6F and G</xref>).</p><fig-group><fig id="fig6" position="float"><label>Figure 6.</label><caption><title>Analysis of synovial cells expressing CD47.</title><p>The gating strategy to identify and sort CD47<sup>Hi</sup> vs. CD47<sup>Lo</sup> cell populations (<bold>A–C</bold>). CD47<sup>Hi</sup> vs. CD47<sup>Lo</sup> cells were identified and isolated from normal and osteoarthritis (OA) synovial tissue (<bold>B</bold>). Chondrogenic differentiation of CD47<sup>Hi</sup> vs. CD47<sup>Lo</sup> cells using pellet culture and stained with Alcian Blue (<bold>D</bold>). GAG quantification of the pellets (<bold>E</bold>). The pellets were also stained with Collagen 2 (Col2) as a marker of mature cartilage ECM (<bold>E, G</bold>). Signifiance determined by1 way ANOVA. <italic>p</italic>&lt;0.05. Scale bars equal 100 µm.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-103332-fig6-v1.tif"/></fig><fig id="fig6s1" position="float" specific-use="child-fig"><label>Figure 6—figure supplement 1.</label><caption><title>Analysis of synovial cells expressing CD47.</title><p>CD47 cells from normal and osteoarthritis (OA) synovium were assayed for the expression of ITAG5 and DPP4/CD26 by flow cytometry. The isotype control shows little to no reactivity. CD47<sup>Hi</sup> cells co-expressed ITAG5 and DPP4/CD26, whereas CD47<sup>Lo</sup> cells did not.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-103332-fig6-figsupp1-v1.tif"/></fig></fig-group><p>These CD47<sup>Hi</sup> and CD47<sup>Lo</sup> populations were then injected into rats that had undergone DMM injury one week prior (<xref ref-type="fig" rid="fig7">Figure 7A</xref>). Rats that received CD47<sup>Hi</sup> cells presented with significantly lower OARSI scores than rats receiving CD47<sup>Lo</sup> cells (<xref ref-type="fig" rid="fig7">Figure 7B–D</xref>), but there was no difference in Krenn scoring between rats which received CD47<sup>Hi</sup> or CD47<sup>Lo</sup> cells (<xref ref-type="fig" rid="fig7">Figure 7B</xref>). When the joint tissues were isolated for histology, it was found that CD47<sup>Hi</sup> cells contributed to the formation of new articular cartilage tissue within the injured joints (<xref ref-type="fig" rid="fig7">Figure 7H–J</xref>); however, this was not observed with CD47<sup>Lo</sup> cells (<xref ref-type="fig" rid="fig7">Figure 7E–G</xref>). Specifically, human cells (tdTomato<sup>+</sup>) were observed within the cartilage of CD47<sup>Hi</sup>-injected rats, and these cells also expressed the chondrogenic markers Sox9 and Prg4 (<xref ref-type="fig" rid="fig7">Figure 7H–J</xref>). In rats that received CD47<sup>Lo</sup> cells, few to no tdTomato cells were observed within the injured cartilage (<xref ref-type="fig" rid="fig7">Figure 7E–G</xref>).</p><fig id="fig7" position="float"><label>Figure 7.</label><caption><title>CD47<sup>Hi</sup> vs. CD47<sup>Lo</sup> cell contribution to cartilage repair in a rat DMM model.</title><p>The CD47<sup>Hi</sup> vs. CD47<sup>Lo</sup> cells were injected into rats that underwent DMM injury (<bold>A</bold>), and it was observed that rats which received the CD47<sup>Hi</sup> cells presented with significantly lower OARSI scores than rats receiving CD47<sup>Lo</sup> cells (<bold>B</bold>) with representative images presented of joints receiving CD47<sup>Hi</sup> (<bold>C</bold>) and CD47<sup>Lo</sup> (<bold>D</bold>) cells. Immunofluorescence analysis demonstrated that the transplanted human CD47<sup>Hi</sup> cells (TdTomato) integrated into the rat articular cartilage and expressed the chondrocyte markers Prg4 and Sox9 (<bold>H–J</bold>). This was not observed in the cartilage of rats that received the CD47<sup>Lo</sup> cells (<bold>E–G</bold>). Scale bars equal 50 µm. Signifiance determined by1 way ANOVA. <italic>p</italic>&lt;0.05.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-103332-fig7-v1.tif"/></fig></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>The synovium plays a vital role in the overall health of the joint (<xref ref-type="bibr" rid="bib5">Berenbaum, 2013</xref>; <xref ref-type="bibr" rid="bib27">Kapoor et al., 2011</xref>). In a normal, healthy joint, synoviocytes assist in nourishing chondrocytes, removing waste and debris, and facilitating gas exchange. However, in OA, the breakdown of the cartilaginous matrix and subsequent phagocytosis of debris by synoviocytes promotes synovitis. This inflammation triggers the release of soluble proinflammatory mediators from the synovium, enhancing cartilage breakdown and perpetuating a vicious cycle. Although OA disrupts the primary function of articular cartilage (to provide cushioning and decrease friction within the joint), it impacts all tissues within the joint environment. The loss of the protective cartilage layer leads to intense pain in affected individuals. Moreover, damaged articular cartilage has limited ability to repair itself due to its avascular and aneural nature (<xref ref-type="bibr" rid="bib40">Masson and Krawetz, 2020</xref>). Current non-surgical treatment strategies for OA focus on alleviating symptoms, such as pain and inflammation. However, there are currently no proven treatments to prevent cartilage loss and promote tissue regrowth. While MSCs from the synovial membrane and synovial fluid have shown tri-lineage differentiation potential in various studies, endogenous articular cartilage repair remains elusive (<xref ref-type="bibr" rid="bib11">De Bari, 2015</xref>; <xref ref-type="bibr" rid="bib57">Sekiya et al., 2021</xref>; <xref ref-type="bibr" rid="bib33">Krawetz et al., 2012</xref>; <xref ref-type="bibr" rid="bib39">Masson et al., 2015</xref>; <xref ref-type="bibr" rid="bib56">Sekiya et al., 2012</xref>). Moreover, distinct sub-populations of synovial MSCs exhibit widely different characteristics, including cell surface protein expression and differentiation potential (<xref ref-type="bibr" rid="bib1">Affan et al., 2019</xref>). This suggests that not all tissue-resident stem cells are created equal and underscores the need for further research into understanding these sub-populations.</p><p>The aim of this project was to characterize different progenitor populations in the synovium of normal and OA knee joints based on their self-renewal capacity, differentiation ability, and cell surface marker profile. However, relying solely on cell surface markers for MSC selection can be unreliable, as not all subpopulations demonstrate a high correlation between marker expression and differentiation potential. Moreover, changes in marker expression under different laboratory conditions can confound MSC characterization. Furthermore, it has been shown that some cell surface markers (such as CD105) may be an artifact of in vitro culturing, as this molecule doesn’t appear to be expressed by MSCs in vivo and is in part responsible for the ability of MSCs to adhere to plastic (<xref ref-type="bibr" rid="bib2">Anderson et al., 2013</xref>; <xref ref-type="bibr" rid="bib6">Cleary et al., 2016</xref>). Therefore, our study utilized single-cell sorting to isolate cells from human knee samples, minimizing exposure to the culture microenvironment before analysis. We found that regardless of in situ marker expression, nearly all clonal cell populations displayed a uniform marker profile consistent with a presumptive MSC phenotype. This strongly suggests that the in vitro microenvironment upregulates and/or stabilizes the expression of the receptors. This notion is supported by our observation (similar to previously published studies) (<xref ref-type="bibr" rid="bib1">Affan et al., 2019</xref>), that the expression of CD105 was acquired only after culture, indicating its potential role as a bystander marker in MSC characterization. Additionally, the expression of CD271 varied among MSC clones, with none of the clones demonstrating multipotential differentiation capacity expressing CD271. This suggests that CD271 may not be a marker of synovial MSCs (<xref ref-type="bibr" rid="bib4">Barilani et al., 2018</xref>). Also interesting was that the distribution of OA MSC subpopulations differed from those in healthy joints, indicating distinct alterations in the synovial niche during OA onset/progression. In future studies, it would be interesting to determine what exact aspects of in vitro culture cause the cells to take on a uniform immunophenotype. Specifically, testing out different media and/or matrix compositions could shed light on this observation.</p><p>In the current study, we have identified a subpopulation of synovial cells that express high levels of CD47. Our findings support the hypothesis that cells expressing high levels of CD47 have robust cartilage regeneration potential. CD47, also known as integrin-associated protein, is a transmembrane protein that plays a pivotal role in immune regulation. It acts as a ‘don't eat me’ signal, inhibiting phagocytosis by macrophages and other immune cells (<xref ref-type="bibr" rid="bib21">Hao et al., 2023</xref>; <xref ref-type="bibr" rid="bib41">Maute et al., 2022</xref>; <xref ref-type="bibr" rid="bib47">Oldenborg, 2013</xref>). It has been shown that overexpression of CD47 allows cells (such as in various cancers) to evade immune surveillance. In stem cell populations, particularly adult stem cells, CD47 plays a crucial role in maintaining self-renewal and tissue regeneration capacities (<xref ref-type="bibr" rid="bib25">Jaiswal et al., 2009</xref>; <xref ref-type="bibr" rid="bib29">Kim et al., 2021</xref>). It regulates stem cell survival and proliferation by interacting with its receptor, SIRPα, on neighboring cells or stromal components. This interaction influences stem cell behavior, homing, and differentiation, shaping tissue homeostasis and repair processes. Its upregulation on dying cells can lead to the inhibition of phagocytosis of these necrotic/apoptotic cells (<xref ref-type="bibr" rid="bib32">Kojima et al., 2016</xref>), leading to the accumulation of cellular debris within the environment, thus perpetuating inflammation. Overall, there is still not much known about how CD47 regulates stem cell/progenitor function, and it would be of interest to experimentally test if the overexpression of CD47 in MSCs can increase their endogenous cartilage regeneration capacity.</p><p>While the clonal derivation and long-term expansion of cells made this experimental design possible, this approach is not without limitations. Firstly, during clonal derivation, cells may acquire genetic mutations or epigenetic alterations due to the stresses of isolation and culture conditions, leading to phenotypic changes and potential change/loss of functionality. Moreover, the process of long-term expansion in vitro can induce replicative senescence, telomere shortening, and genomic instability, compromising the quality and integrity of the cell population over time. This could account in part for the majority of clones we derived losing the ability to proliferate before we could achieve a sufficient number of cells for the downstream analyses. Furthermore, cells cultured in vitro often face challenges in recapitulating the complex microenvironment and dynamic interactions present with their in vivo niche(s), potentially altering their behavior and functional properties. As such, the reliance on exogenous growth factors, culture media, and artificial substrates to support cell growth and expansion introduces variability and may not fully mimic the physiological cues present in the native tissue environment. Such discrepancies can impact the reliability and reproducibility of experimental outcomes and may hinder the successful clinical translation of cell-based therapies. Yet, even with these challenges, we have presented compelling evidence demonstrating that a sub-population of cells exists within the human synovial membrane (under normal and OA conditions) that can contribute to articular cartilage regeneration.</p><p>In conclusion, while MSCs hold promise for OA treatment, the heterogeneity within MSC populations presents challenges for their effective utilization. The development of effective and reproducible protocols for MSC identification/characterization are necessary to ensure the selection of MSCs with the greatest potential for joint repair and regeneration. With this knowledge, we have the best chance of developing novel cell therapies that will benefit the growing number of patients suffering from OA.</p></sec><sec id="s4" sec-type="methods"><title>Methods</title><sec id="s4-1"><title>Study participants</title><p>This study protocol was approved by the University of Calgary Human Research Ethics Board (REB15-0005 and REB15-0880). The n=18 (with an additional n=4 for the validation phase) normal control cadaveric donations were harvested within 4 hr of death and were at least 18 years old with no history of arthritis, joint injury or surgery, no prescription anti-inflammatory medications, and no co-morbidities. The n=15 (with an additional n=4 for the validation phase) knee OA sample donors were diagnosed by an orthopedic surgeon at the University of Calgary based on clinical symptoms with radiographic evidence in accordance with American College of Rheumatology criteria (<xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>). All OA participants provided written consent to participate. All testing was carried out in accordance with the Declaration of Helsinki.</p></sec><sec id="s4-2"><title>Experimental outline</title><p>The experimental outline of the study is presented in <xref ref-type="fig" rid="fig1s3">Figure 1—figure supplement 3</xref>.</p></sec><sec id="s4-3"><title>Cell sorting and flow cytometry</title><p>Synovial cells were isolated as previously described (<xref ref-type="bibr" rid="bib1">Affan et al., 2019</xref>). Briefly, 5 mm² tissue samples were digested using 1 mg/mL Collagenase IV (Thermo Scientific) at 37 °C with shaking for 90 min. The resulting cell suspension was filtered using a 70 µm filter and centrifuged at 5000 rpm for 6 min. The cell pellet was then washed with 1 x PBS (Lonza-BioWhittaker) and re-suspended in 100 µL of MesenCult Media (StemCell Technologies).</p><p>Cells were immunostained for mesenchymal stem cell (MSC) markers, including CD90 (Clone 5E10, PE), CD271 (Clone C40-1457, BV421), CD105 (Clone 266, BV650), CD73 (Clone AD2, APC), and CD44 (Clone G44-26, PE-Cy7) (all from BD Bioscience), according to the manufacturers' protocols. Additionally, cells were stained with the viability marker FVS510 (BV510) at a 1:100 dilution for 30 min on ice and with CD68 (Clone Y1/82 A, FITC) to target the macrophage population. Positive compensation controls were conducted using Ultracomp eBeads (eBioscience), and unstained cells served as negative controls.</p><p>The labeled cells were sorted using a BD FACS Aria Fusion with an indexed sorting protocol. The instrument was configured with a 100 µm sorting nozzle, a ‘single cell’ mask, a 2 X neutral density filter, and a flow rate below 50% of the maximum. Dead cells (FVS510<sup>+</sup>) and macrophages (CD68<sup>+</sup>) were excluded, and the remaining cells were collected into 96-well plates (1 cell per well) containing Dulbecco’s modified Eagle’s medium F-12 (DMEM/F-12) with MesenCult-SF attachment substrate (StemCell Technologies) and 1% antibiotic-antimycotic (Life Technologies). The sorted cells were cultured until they reached 70–80% confluency, then transferred to T-25 flasks (Greiner). Once the cultures reached ~70% confluency, the cells were washed with 1 x PBS (Lonza-BioWhittaker), trypsinized (Corning), and re-plated. Media was changed every 2 days, and cells were passaged until they expanded into 4 x T-75 flasks.</p><p>During the validation phase of the study, bulk sorting was performed directly from dissociated synovium without prior cell expansion. Cell suspensions from a new cohort (n=4 normal and n=4 osteoarthritis synovium) were isolated using the same digestion method described earlier. The cells were stained with the markers CD68, CD90, CD73, CD44, and the viability marker FVS510, as previously detailed. Sorting was performed using the BD FACS Aria Fusion, and cells were sorted into 5 mL tubes containing 500 µL of media. Instead of sorting one cell per well, the strategy involved gating out CD68 + and dead cells, followed by sorting CD90<sup>+</sup>CD73<sup>+</sup>CD44<sup>+</sup> cells into one tube and the remaining cells (a mixture of all populations except CD90<sup>+</sup>CD73<sup>+</sup>CD44<sup>+</sup>) into a separate tube. This sorting was conducted using a 100 µm sorting nozzle, a ‘purity’ mask, a 2 X neutral density filter, and a flow rate of 5/11. Both positive and negative populations were transferred to 48-well plates and expanded until they reached 70% confluency in 4 x T-75 flasks. These cells were subsequently characterized for their differentiation potential and underwent in vitro flow cytometry analysis as previously described.</p></sec><sec id="s4-4"><title>Differentiation analysis</title><p>Expanded clonal cells were induced to differentiate into bone, cartilage, and fat as previously (<xref ref-type="bibr" rid="bib1">Affan et al., 2019</xref>; <xref ref-type="bibr" rid="bib34">Krawetz et al., 2022</xref>). For each differentiation protocol, 5×10⁵ cells were either plated (for osteogenic and adipogenic protocols) or pelleted and plated (for chondrogenic protocols) in 24-well plates. Cells were incubated for 21 days in either osteogenic, chondrogenic, or adipogenic media, with the media changed every 2 days: <bold>Osteogenic media</bold>: DMEM/F-12, 10% FBS, 1% antibiotic-antimycotic, 1% MEM non-essential amino acids (NEAA), 10⁻⁴M dexamethasone, 50 µg/mL L-ascorbic acid (AA), and 10 mM β-glycerophosphate (all from Sigma). <bold>Chondrogenic media</bold>: DMEM/F-12, 10% FBS, 1% antibiotic-antimycotic, 1% MEM NEAA (Gibco), 10 nM dexamethasone, 50 mg/mL AA, NaOH, 10 ng/mL TGF-β3 (Peprotech), 500 ng/mL BMP-2 (Peprotech), sodium pyruvate (Gibco), and insulin-transferrin-selenium (ITS, Lonza-BioWhittaker). <bold>Adipogenic media</bold>: DMEM/F-12, 10% FBS, 1% antibiotic-antimycotic, 1% MEM NEAA, 1 μM dexamethasone, 10 µM insulin, 200 µM indomethacin, and 500 µM isobutylmethylxanthine (all from Sigma).</p></sec><sec id="s4-5"><title>Quantitative PCR (qPCR)</title><p>Cells were washed with 1 X PBS. RNA was extracted using TRIzol reagent (Invitrogen) from osteogenic and adipogenic cells, and using the Total RNA Kit I (OMEGA bio-tek) from chondrogenic cells, following manufacturers' protocols. The isolated mRNA was stored at –80 °C for later analysis. To generate cDNA, 10 μL of mRNA was mixed with 10 μL of cDNA Master Mix (High-Capacity cDNA kit, Applied Biosystems) and incubated in a thermocycler (Bio-Rad) for 2 hr. The samples were then stored at –20 °C. qPCR was used to quantify the gene expression of specific markers: <bold>Osteoblast markers</bold>: <italic>Sp7, Runx2</italic>, <bold>Chondrocyte markers</bold>: <italic>Sox9, Col2a</italic>, <bold>Adipocyte markers</bold>: <italic>Adipoq</italic>. Triplicate reactions per sample were performed in either 384-well or 96-well plates (Applied Biosystems). Reactions included 0.5 µL of the specific probe, 5 µL of TaqMan Universal PCR Master Mix (Applied Biosystems), 3.5 µL ultrapure H₂O, and 1 µL cDNA. Gene expression was standardized using the 18 S ribosomal RNA, calculated via the DeltaDeltaCT method.</p></sec><sec id="s4-6"><title>In vitro histology</title><p>Cells were fixed with 10% neutral buffered formalin (NBF) at room temperature for 1 hr. <bold>Osteogenic cultures</bold> were stained with 20 mg/mL alizarin red (Sigma) for 45 min. <bold>Adipogenic cultures</bold> were washed, incubated with 60% isopropanol, and stained with Oil Red O for 15 min, followed by Harris Hematoxylin. <bold>Chondrogenic cultures</bold> were treated with 1% acetic acid and stained with 0.1% Safranin O for 5 min as previously described (<xref ref-type="bibr" rid="bib1">Affan et al., 2019</xref>).</p></sec><sec id="s4-7"><title>Destabilization of the medial meniscus (DMM) injury model</title><p>Animal studies were carried out in accordance with the recommendations in the Canadian Council on Animal Care Guidelines. Animal protocols and surgical procedures in this study were approved by the University of Calgary Health Sciences Animal Care Committee.</p><p>Ten-week-old Lewis rats were used for the DMM model. Males weighed ~250 g (±50 g), and females weighed ~175 g (±20 g) at the time of surgery. Rats were anesthetized with isoflurane, and a medial para-patellar arthrotomy was performed under a microscope. The fat pad over the cranial horn of the medial meniscus was retracted, and sectioning of the medial meniscotibial ligament destabilized the meniscus (<xref ref-type="bibr" rid="bib9">Das et al., 2023</xref>; <xref ref-type="bibr" rid="bib23">Iqbal et al., 2016</xref>). Sham-operated rats served as controls, receiving surgery without injury. The joint capsule and skin were closed with sutures and adhesive.</p></sec><sec id="s4-8"><title>Cell injection</title><p>Once a sufficient number of cells had been obtained, the purified synovial cells were incubated with the following mix overnight (~12 hr) at 37 °C, 2% O<sub>2</sub>: 5  mL MesenCult, 5  μL tdTomato lentivirus (where tdTomato was driven by the EF1-alpha promoter), and 2  μL of Polybrene (8  μg/mL, Sigma). Medium was changed the following day. The cells were then sorted for tdTomato expression and the positive cells were used for the xenotransplantation experiments.</p><p>Control groups included six rats with sham surgery and six rats that underwent DMM injected with PBS alone. The injection involved a 30 G needle placed through the patella tendon into the joint space, with 10 µL of sterile DPBS containing 100,000 cells injected 1 week post-DMM surgery. Sample size as follows for the initial experiments: DMM (MSC injected) n=3 rats per cell line, 8 cell lines used (normal MSC x2 and non-MSC x2, OA MSC x2 and non-MSC x2). Sample size as follows for the CD47 experiments: DMM (CD47<sup>Hi</sup> injected) n=2 rats per cell line, six cell lines used (three normal, three OA), (CD47<sup>Lo</sup> injected) n=2 rats per cell line, six cell lines used (three normal, three OA).</p></sec><sec id="s4-9"><title>Histology and OA grading</title><p>Four weeks post-cell injection (5 weeks post-DMM), rats were sacrificed. Knee joints were dissected, fixed in 4% formalin, decalcified, embedded in paraffin, and sectioned. Sections were stained with Safranin O to visualize proteoglycans and graded according to OARSI guidelines for rat knees.</p><p>Immunohistochemistry analysis was performed on the rat knee sections. Antigen retrieval was achieved using 10 mM sodium citrate (pH 6.0), and non-specific blocking was prevented using goat serum (1:500 dilution in TBST). tdTomato (AB8181, Origene), Collagen 2 (Col2; Clone # II-II6B3, DSHB), PRG4 (Clone # 9G3, Millipore), Ccl2 (Clone # 2D8, Thermo Fisher), Ki67 (Clone # SolA15, ThermoFisher), Sox9 (Clone # 7H13L8, Thermo Fisher) or CD47 (Clone # B6H12, Thermo Fisher) were applied to the sections and incubated overnight. For the Col2 staining, an additional hyaluronidase (Sigma) treatment step was added. Secondary controls were also performed, where only secondary antibody was applied to the sections (no primary antibody). All slides were mounted using EverBrite Hardset Mounting Medium with 4′,6-diamidino-2-phenylindole (DAPI, Biotium). Slides were imaged using a Plan-Apochromat objective on an Axio Scan.Z1 Slide Scanner microscope (Carl Zeiss).</p></sec><sec id="s4-10"><title>Tissue cytometry</title><p>TissueQuest software was used for immunofluorescent image analysis. After nuclear segmentation using DAPI, each marker channel was analyzed, with gates and thresholds set using non-stained controls. Data were visualized using scattergrams and histograms, and statistical analysis was done using GraphPad.</p></sec><sec id="s4-11"><title>Quantitative shotgun proteomics using Tandem Mass Tags (TMT-6) labeling</title><p>Synovial membrane-derived clones were lysed and sonicated. Cellular proteins were quantified and isolated for TMT-6 plex shotgun proteomics. LC-MS/MS analysis was conducted at the Southern Alberta Mass Spectrometry core facility (<xref ref-type="bibr" rid="bib9">Das et al., 2023</xref>). Peptides were separated using C18 columns, and data were analyzed using MaxQuant software and statistical tools in R.</p></sec><sec id="s4-12"><title>Reactome pathway analysis</title><p>The STRING database was used to identify protein interconnectivity, with analysis done in Metascape for functional enrichment, interactome analysis, and gene annotation. Human protein data were analyzed with a 1% false discovery rate.</p></sec><sec id="s4-13"><title>Statistics</title><p>Statistical analysis was conducted using GraphPad Prism 7. Data were presented as mean ± standard deviation (SD). The Student’s t-test was used for group comparisons, and Spearman correlation was applied for association analyses. Significance was set at <italic>p</italic>&lt;0.05, with data visualized using IBM SPSS.</p></sec></sec></body><back><sec sec-type="additional-information" id="s5"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Formal analysis, Investigation, Methodology, Writing – original draft</p></fn><fn fn-type="con" id="con2"><p>Formal analysis, Investigation, Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con3"><p>Formal analysis, Investigation, Methodology</p></fn><fn fn-type="con" id="con4"><p>Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con5"><p>Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con6"><p>Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con7"><p>Conceptualization, Investigation, Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con8"><p>Supervision, Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con9"><p>Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con10"><p>Investigation, Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con11"><p>Investigation, Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con12"><p>Conceptualization, Resources, Formal analysis, Supervision, Funding acquisition, Investigation, Writing – original draft, Project administration, Writing – review and editing</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Human subjects: This study protocol was approved by the University of Calgary Human Research Ethics Board (REB15-0005 and REB15-0880). All OA participants provided written consent to participate.</p></fn><fn fn-type="other"><p>Animal studies were carried out in accordance with the recommendations in the Canadian Council on Animal Care Guidelines. Animal protocols and surgical procedures in this study were approved by the University of Calgary Health Sciences Animal Care Committee (Ethics ID AC20-0042).</p></fn></fn-group></sec><sec sec-type="supplementary-material" id="s6"><title>Additional files</title><supplementary-material id="supp1"><label>Supplementary file 1.</label><caption><title>Summary of the participants in the study.</title><p>There was no difference in the ages between the normal and OA group (<italic>P</italic>=0.13).</p></caption><media xlink:href="elife-103332-supp1-v1.docx" mimetype="application" mime-subtype="docx"/></supplementary-material><supplementary-material id="supp2"><label>Supplementary file 2.</label><caption><title>Summary of all clonal lines derived from all patients included in the study.</title><p>Gray highlight: Patient sample did not yield any cell growth following single cell sorting. Blue highlight: Clonal cell line yielded enough number of cells for full characterization.</p></caption><media xlink:href="elife-103332-supp2-v1.docx" mimetype="application" mime-subtype="docx"/></supplementary-material><supplementary-material id="supp3"><label>Supplementary file 3.</label><caption><title>Summary of the self-renewal capacity (population doublings) from all clonal lines derived in the study.</title></caption><media xlink:href="elife-103332-supp3-v1.docx" mimetype="application" mime-subtype="docx"/></supplementary-material><supplementary-material id="supp4"><label>Supplementary file 4.</label><caption><title>Summary of the cell surface marker expression (in situ and in vitro) and differentiation potential of clones derived from normal individuals.</title></caption><media xlink:href="elife-103332-supp4-v1.docx" mimetype="application" mime-subtype="docx"/></supplementary-material><supplementary-material id="supp5"><label>Supplementary file 5.</label><caption><title>Summary of the cell surface marker expression (in situ and in vitro) and differentiation potential of clones derived from OA patients.</title></caption><media xlink:href="elife-103332-supp5-v1.docx" mimetype="application" mime-subtype="docx"/></supplementary-material><supplementary-material id="supp6"><label>Supplementary file 6.</label><caption><title>Summary of marker expression and differentiation potential from CD90<sup>+</sup>CD44<sup>+</sup>CD73<sup>+</sup> cells derived from normal and OA synovium.</title></caption><media xlink:href="elife-103332-supp6-v1.docx" mimetype="application" mime-subtype="docx"/></supplementary-material><supplementary-material id="supp7"><label>Supplementary file 7.</label><caption><title>Shotgun proteomics of proteins from mesenchymal stem cells and non-mesenchymal stem cells identified without constraint by enzyme specificity rules during spectrum-to-sequence matching.</title></caption><media xlink:href="elife-103332-supp7-v1.xlsx" mimetype="application" mime-subtype="xlsx"/></supplementary-material><supplementary-material id="mdar"><label>MDAR checklist</label><media xlink:href="elife-103332-mdarchecklist1-v1.docx" mimetype="application" mime-subtype="docx"/></supplementary-material></sec><sec sec-type="data-availability" id="s7"><title>Data availability</title><p>Data available within the article or its supplementary materials.</p></sec><ack id="ack"><title>Acknowledgements</title><p>The authors would like to thank Dr. Yiping Liu of the Cumming School of Medicine Flow Cytometry Facility for assistance with FACS and the Cumming School of Medicine ARC staff for assistance with animal husbandry. Natural Sciences and Engineering Research Council (NSERC) of Canada RGPIN-2014–04586 (RJK). Canada Foundation for Innovation (RJK). Calgary Foundation, Grace Glaum Professorship (RJK). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Affan</surname><given-names>A</given-names></name><name><surname>Al-Jezani</surname><given-names>N</given-names></name><name><surname>Railton</surname><given-names>P</given-names></name><name><surname>Powell</surname><given-names>JN</given-names></name><name><surname>Krawetz</surname><given-names>RJ</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Multiple mesenchymal progenitor cell subtypes with distinct functional potential are present within the intimal layer of the hip synovium</article-title><source>BMC Musculoskeletal Disorders</source><volume>20</volume><elocation-id>125</elocation-id><pub-id pub-id-type="doi">10.1186/s12891-019-2495-2</pub-id><pub-id pub-id-type="pmid">30909916</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anderson</surname><given-names>P</given-names></name><name><surname>Carrillo-Gálvez</surname><given-names>AB</given-names></name><name><surname>García-Pérez</surname><given-names>A</given-names></name><name><surname>Cobo</surname><given-names>M</given-names></name><name><surname>Martín</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>CD105 (endoglin)-negative murine mesenchymal stromal cells define a new multipotent subpopulation with distinct differentiation and immunomodulatory capacities</article-title><source>PLOS ONE</source><volume>8</volume><elocation-id>e76979</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0076979</pub-id><pub-id pub-id-type="pmid">24124603</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arden</surname><given-names>NK</given-names></name><name><surname>Perry</surname><given-names>TA</given-names></name><name><surname>Bannuru</surname><given-names>RR</given-names></name><name><surname>Bruyère</surname><given-names>O</given-names></name><name><surname>Cooper</surname><given-names>C</given-names></name><name><surname>Haugen</surname><given-names>IK</given-names></name><name><surname>Hochberg</surname><given-names>MC</given-names></name><name><surname>McAlindon</surname><given-names>TE</given-names></name><name><surname>Mobasheri</surname><given-names>A</given-names></name><name><surname>Reginster</surname><given-names>JY</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Non-surgical management of knee osteoarthritis: comparison of ESCEO and OARSI 2019 guidelines</article-title><source>Nature Reviews. Rheumatology</source><volume>17</volume><fpage>59</fpage><lpage>66</lpage><pub-id pub-id-type="doi">10.1038/s41584-020-00523-9</pub-id><pub-id pub-id-type="pmid">33116279</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barilani</surname><given-names>M</given-names></name><name><surname>Banfi</surname><given-names>F</given-names></name><name><surname>Sironi</surname><given-names>S</given-names></name><name><surname>Ragni</surname><given-names>E</given-names></name><name><surname>Guillaumin</surname><given-names>S</given-names></name><name><surname>Polveraccio</surname><given-names>F</given-names></name><name><surname>Rosso</surname><given-names>L</given-names></name><name><surname>Moro</surname><given-names>M</given-names></name><name><surname>Astori</surname><given-names>G</given-names></name><name><surname>Pozzobon</surname><given-names>M</given-names></name><name><surname>Lazzari</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Low-affinity Nerve Growth Factor Receptor (CD271) heterogeneous expression in adult and fetal mesenchymal stromal cells</article-title><source>Scientific Reports</source><volume>8</volume><elocation-id>9321</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-018-27587-8</pub-id><pub-id pub-id-type="pmid">29915318</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berenbaum</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Osteoarthritis as an inflammatory disease (osteoarthritis is not osteoarthrosis!)</article-title><source>Osteoarthritis and Cartilage</source><volume>21</volume><fpage>16</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1016/j.joca.2012.11.012</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cleary</surname><given-names>MA</given-names></name><name><surname>Narcisi</surname><given-names>R</given-names></name><name><surname>Focke</surname><given-names>K</given-names></name><name><surname>van der Linden</surname><given-names>R</given-names></name><name><surname>Brama</surname><given-names>PAJ</given-names></name><name><surname>van Osch</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Expression of CD105 on expanded mesenchymal stem cells does not predict their chondrogenic potential</article-title><source>Osteoarthritis and Cartilage</source><volume>24</volume><fpage>868</fpage><lpage>872</lpage><pub-id pub-id-type="doi">10.1016/j.joca.2015.11.018</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Collins</surname><given-names>FL</given-names></name><name><surname>Roelofs</surname><given-names>AJ</given-names></name><name><surname>Symons</surname><given-names>RA</given-names></name><name><surname>Kania</surname><given-names>K</given-names></name><name><surname>Campbell</surname><given-names>E</given-names></name><name><surname>Collie-Duguid</surname><given-names>ESR</given-names></name><name><surname>Riemen</surname><given-names>AHK</given-names></name><name><surname>Clark</surname><given-names>SM</given-names></name><name><surname>De Bari</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Taxonomy of fibroblasts and progenitors in the synovial joint at single-cell resolution</article-title><source>Annals of the Rheumatic Diseases</source><volume>82</volume><fpage>428</fpage><lpage>437</lpage><pub-id pub-id-type="doi">10.1136/ard-2021-221682</pub-id><pub-id pub-id-type="pmid">36414376</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Das</surname><given-names>N</given-names></name><name><surname>Schmidt</surname><given-names>TA</given-names></name><name><surname>Krawetz</surname><given-names>RJ</given-names></name><name><surname>Dufour</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Proteoglycan 4: from mere lubricant to regulator of tissue homeostasis and inflammation</article-title><source>BioEssays</source><volume>41</volume><elocation-id>1800166</elocation-id><pub-id pub-id-type="doi">10.1002/bies.201800166</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Das</surname><given-names>N</given-names></name><name><surname>de Almeida</surname><given-names>LGN</given-names></name><name><surname>Derakhshani</surname><given-names>A</given-names></name><name><surname>Young</surname><given-names>D</given-names></name><name><surname>Mehdinejadiani</surname><given-names>K</given-names></name><name><surname>Salo</surname><given-names>P</given-names></name><name><surname>Rezansoff</surname><given-names>A</given-names></name><name><surname>Jay</surname><given-names>GD</given-names></name><name><surname>Sommerhoff</surname><given-names>CP</given-names></name><name><surname>Schmidt</surname><given-names>TA</given-names></name><name><surname>Krawetz</surname><given-names>R</given-names></name><name><surname>Dufour</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Tryptase β regulation of joint lubrication and inflammation via proteoglycan-4 in osteoarthritis</article-title><source>Nature Communications</source><volume>14</volume><elocation-id>1910</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-023-37598-3</pub-id><pub-id pub-id-type="pmid">37024468</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Bari</surname><given-names>C</given-names></name><name><surname>Dell’Accio</surname><given-names>F</given-names></name><name><surname>Tylzanowski</surname><given-names>P</given-names></name><name><surname>Luyten</surname><given-names>FP</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Multipotent mesenchymal stem cells from adult human synovial membrane</article-title><source>Arthritis &amp; Rheumatism</source><volume>44</volume><fpage>1928</fpage><lpage>1942</lpage><pub-id pub-id-type="doi">10.1002/1529-0131(200108)44:8&lt;1928::AID-ART331&gt;3.0.CO;2-P</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Bari</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Are mesenchymal stem cells in rheumatoid arthritis the good or bad guys?</article-title><source>Arthritis Research &amp; Therapy</source><volume>17</volume><elocation-id>113</elocation-id><pub-id pub-id-type="doi">10.1186/s13075-015-0634-1</pub-id><pub-id pub-id-type="pmid">25929877</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deshmane</surname><given-names>SL</given-names></name><name><surname>Kremlev</surname><given-names>S</given-names></name><name><surname>Amini</surname><given-names>S</given-names></name><name><surname>Sawaya</surname><given-names>BE</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Monocyte chemoattractant protein-1 (MCP-1): an overview</article-title><source>Journal of Interferon &amp; Cytokine Research</source><volume>29</volume><fpage>313</fpage><lpage>326</lpage><pub-id pub-id-type="doi">10.1089/jir.2008.0027</pub-id><pub-id pub-id-type="pmid">19441883</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Witte</surname><given-names>SFH</given-names></name><name><surname>Luk</surname><given-names>F</given-names></name><name><surname>Sierra Parraga</surname><given-names>JM</given-names></name><name><surname>Gargesha</surname><given-names>M</given-names></name><name><surname>Merino</surname><given-names>A</given-names></name><name><surname>Korevaar</surname><given-names>SS</given-names></name><name><surname>Shankar</surname><given-names>AS</given-names></name><name><surname>O’Flynn</surname><given-names>L</given-names></name><name><surname>Elliman</surname><given-names>SJ</given-names></name><name><surname>Roy</surname><given-names>D</given-names></name><name><surname>Betjes</surname><given-names>MGH</given-names></name><name><surname>Newsome</surname><given-names>PN</given-names></name><name><surname>Baan</surname><given-names>CC</given-names></name><name><surname>Hoogduijn</surname><given-names>MJ</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Immunomodulation by therapeutic Mesenchymal Stromal Cells (MSC) is triggered through phagocytosis of MSC by monocytic cells</article-title><source>Stem Cells</source><volume>36</volume><fpage>602</fpage><lpage>615</lpage><pub-id pub-id-type="doi">10.1002/stem.2779</pub-id><pub-id pub-id-type="pmid">29341339</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dimarino</surname><given-names>AM</given-names></name><name><surname>Caplan</surname><given-names>AI</given-names></name><name><surname>Bonfield</surname><given-names>TL</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Mesenchymal stem cells in tissue repair</article-title><source>Frontiers in Immunology</source><volume>4</volume><elocation-id>201</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2013.00201</pub-id><pub-id pub-id-type="pmid">24027567</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dominici</surname><given-names>M</given-names></name><name><surname>Le Blanc</surname><given-names>K</given-names></name><name><surname>Mueller</surname><given-names>I</given-names></name><name><surname>Slaper-Cortenbach</surname><given-names>I</given-names></name><name><surname>Marini F.</surname><given-names>C</given-names></name><name><surname>Krause</surname><given-names>DSS</given-names></name><name><surname>Deans</surname><given-names>RJJ</given-names></name><name><surname>Keating</surname><given-names>A</given-names></name><name><surname>Prockop</surname><given-names>DJJ</given-names></name><name><surname>Horwitz</surname><given-names>EMM</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Minimal criteria for defining multipotent mesenchymal stromal cells</article-title><source>The International Society for Cellular Therapy Position Statement. Cytotherapy</source><volume>8</volume><fpage>315</fpage><lpage>317</lpage><pub-id pub-id-type="doi">10.1080/14653240600855905</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fellows</surname><given-names>CR</given-names></name><name><surname>Matta</surname><given-names>C</given-names></name><name><surname>Zakany</surname><given-names>R</given-names></name><name><surname>Khan</surname><given-names>IM</given-names></name><name><surname>Mobasheri</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Adipose, bone marrow and synovial joint-derived mesenchymal stem cells for cartilage repair</article-title><source>Frontiers in Genetics</source><volume>7</volume><elocation-id>213</elocation-id><pub-id pub-id-type="doi">10.3389/fgene.2016.00213</pub-id><pub-id pub-id-type="pmid">28066501</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fernandes</surname><given-names>TL</given-names></name><name><surname>Kimura</surname><given-names>HA</given-names></name><name><surname>Pinheiro</surname><given-names>CCG</given-names></name><name><surname>Shimomura</surname><given-names>K</given-names></name><name><surname>Nakamura</surname><given-names>N</given-names></name><name><surname>Ferreira</surname><given-names>JR</given-names></name><name><surname>Gomoll</surname><given-names>AH</given-names></name><name><surname>Hernandez</surname><given-names>AJ</given-names></name><name><surname>Bueno</surname><given-names>DF</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Human synovial mesenchymal stem cells good manufacturing practices for articular cartilage regeneration</article-title><source>Tissue Engineering Part C</source><volume>24</volume><fpage>709</fpage><lpage>716</lpage><pub-id pub-id-type="doi">10.1089/ten.tec.2018.0219</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Futami</surname><given-names>I</given-names></name><name><surname>Ishijima</surname><given-names>M</given-names></name><name><surname>Kaneko</surname><given-names>H</given-names></name><name><surname>Tsuji</surname><given-names>K</given-names></name><name><surname>Ichikawa-Tomikawa</surname><given-names>N</given-names></name><name><surname>Sadatsuki</surname><given-names>R</given-names></name><name><surname>Muneta</surname><given-names>T</given-names></name><name><surname>Arikawa-Hirasawa</surname><given-names>E</given-names></name><name><surname>Sekiya</surname><given-names>I</given-names></name><name><surname>Kaneko</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Isolation and characterization of multipotential mesenchymal cells from the mouse synovium</article-title><source>PLOS ONE</source><volume>7</volume><elocation-id>e45517</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0045517</pub-id><pub-id pub-id-type="pmid">23029067</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grandi</surname><given-names>FC</given-names></name><name><surname>Bhutani</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Epigenetic therapies for osteoarthritis</article-title><source>Trends in Pharmacological Sciences</source><volume>41</volume><fpage>557</fpage><lpage>569</lpage><pub-id pub-id-type="doi">10.1016/j.tips.2020.05.008</pub-id><pub-id pub-id-type="pmid">32586653</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hafsi</surname><given-names>K</given-names></name><name><surname>McKay</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Lana</surname><given-names>JF</given-names></name><name><surname>Macedo</surname><given-names>A</given-names></name><name><surname>Santos</surname><given-names>GS</given-names></name><name><surname>Murrell</surname><given-names>WD</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Nutritional, metabolic and genetic considerations to optimise regenerative medicine outcome for knee osteoarthritis</article-title><source>Journal of Clinical Orthopaedics and Trauma</source><volume>10</volume><fpage>2</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1016/j.jcot.2018.10.004</pub-id><pub-id pub-id-type="pmid">30705524</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hao</surname><given-names>Y</given-names></name><name><surname>Zhou</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>B</given-names></name><name><surname>Cheng</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>The CD47-SIRPα axis is a promising target for cancer immunotherapies</article-title><source>International Immunopharmacology</source><volume>120</volume><elocation-id>110255</elocation-id><pub-id pub-id-type="doi">10.1016/j.intimp.2023.110255</pub-id><pub-id pub-id-type="pmid">37187126</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harris</surname><given-names>Q</given-names></name><name><surname>Seto</surname><given-names>J</given-names></name><name><surname>O’Brien</surname><given-names>K</given-names></name><name><surname>Lee</surname><given-names>PS</given-names></name><name><surname>Kondo</surname><given-names>C</given-names></name><name><surname>Heard</surname><given-names>BJ</given-names></name><name><surname>Hart</surname><given-names>DA</given-names></name><name><surname>Krawetz</surname><given-names>RJ</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Monocyte chemotactic protein-1 inhibits chondrogenesis of synovial mesenchymal progenitor cells: an in vitro study</article-title><source>Stem Cells</source><volume>31</volume><fpage>2253</fpage><lpage>2265</lpage><pub-id pub-id-type="doi">10.1002/stem.1477</pub-id><pub-id pub-id-type="pmid">23836536</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iqbal</surname><given-names>SM</given-names></name><name><surname>Leonard</surname><given-names>C</given-names></name><name><surname>Regmi</surname><given-names>SC</given-names></name><name><surname>De Rantere</surname><given-names>D</given-names></name><name><surname>Tailor</surname><given-names>P</given-names></name><name><surname>Ren</surname><given-names>G</given-names></name><name><surname>Ishida</surname><given-names>H</given-names></name><name><surname>Hsu</surname><given-names>C</given-names></name><name><surname>Abubacker</surname><given-names>S</given-names></name><name><surname>Pang</surname><given-names>DS</given-names></name><name><surname>Salo</surname><given-names>PT</given-names></name><name><surname>Vogel</surname><given-names>HJ</given-names></name><name><surname>Hart</surname><given-names>DA</given-names></name><name><surname>Waterhouse</surname><given-names>CC</given-names></name><name><surname>Jay</surname><given-names>GD</given-names></name><name><surname>Schmidt</surname><given-names>TA</given-names></name><name><surname>Krawetz</surname><given-names>RJ</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Lubricin/Proteoglycan 4 binds to and regulates the activity of Toll-Like Receptors In Vitro</article-title><source>Scientific Reports</source><volume>6</volume><elocation-id>18910</elocation-id><pub-id pub-id-type="doi">10.1038/srep18910</pub-id><pub-id pub-id-type="pmid">26752378</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jablonski</surname><given-names>CL</given-names></name><name><surname>Leonard</surname><given-names>C</given-names></name><name><surname>Salo</surname><given-names>P</given-names></name><name><surname>Krawetz</surname><given-names>RJ</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>CCL2 But Not CCR2 is required for spontaneous articular cartilage regeneration post-injury</article-title><source>Journal of Orthopaedic Research</source><volume>37</volume><fpage>2561</fpage><lpage>2574</lpage><pub-id pub-id-type="doi">10.1002/jor.24444</pub-id><pub-id pub-id-type="pmid">31424112</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jaiswal</surname><given-names>S</given-names></name><name><surname>Jamieson</surname><given-names>CHM</given-names></name><name><surname>Pang</surname><given-names>WW</given-names></name><name><surname>Park</surname><given-names>CY</given-names></name><name><surname>Chao</surname><given-names>MP</given-names></name><name><surname>Majeti</surname><given-names>R</given-names></name><name><surname>Traver</surname><given-names>D</given-names></name><name><surname>van Rooijen</surname><given-names>N</given-names></name><name><surname>Weissman</surname><given-names>IL</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis</article-title><source>Cell</source><volume>138</volume><fpage>271</fpage><lpage>285</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2009.05.046</pub-id><pub-id pub-id-type="pmid">19632178</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jia</surname><given-names>Z</given-names></name><name><surname>Liu</surname><given-names>Q</given-names></name><name><surname>Liang</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Xu</surname><given-names>X</given-names></name><name><surname>Ouyang</surname><given-names>K</given-names></name><name><surname>Xiong</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>D</given-names></name><name><surname>Duan</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Repair of articular cartilage defects with intra-articular injection of autologous rabbit synovial fluid-derived mesenchymal stem cells</article-title><source>Journal of Translational Medicine</source><volume>16</volume><elocation-id>123</elocation-id><pub-id pub-id-type="doi">10.1186/s12967-018-1485-8</pub-id><pub-id pub-id-type="pmid">29739472</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kapoor</surname><given-names>M</given-names></name><name><surname>Martel-Pelletier</surname><given-names>J</given-names></name><name><surname>Lajeunesse</surname><given-names>D</given-names></name><name><surname>Pelletier</surname><given-names>JP</given-names></name><name><surname>Fahmi</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Role of proinflammatory cytokines in the pathophysiology of osteoarthritis</article-title><source>Nature Reviews. Rheumatology</source><volume>7</volume><fpage>33</fpage><lpage>42</lpage><pub-id pub-id-type="doi">10.1038/nrrheum.2010.196</pub-id><pub-id pub-id-type="pmid">21119608</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>J-H</given-names></name><name><surname>Jo</surname><given-names>CH</given-names></name><name><surname>Kim</surname><given-names>H-R</given-names></name><name><surname>Hwang</surname><given-names>Y-I</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Comparison of immunological characteristics of mesenchymal stem cells from the periodontal ligament, umbilical cord, and adipose tissue</article-title><source>Stem Cells International</source><volume>2018</volume><elocation-id>8429042</elocation-id><pub-id pub-id-type="doi">10.1155/2018/8429042</pub-id><pub-id pub-id-type="pmid">29760736</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>GH</given-names></name><name><surname>Bae</surname><given-names>YK</given-names></name><name><surname>Kwon</surname><given-names>JH</given-names></name><name><surname>Kim</surname><given-names>M</given-names></name><name><surname>Choi</surname><given-names>SJ</given-names></name><name><surname>Oh</surname><given-names>W</given-names></name><name><surname>Um</surname><given-names>S</given-names></name><name><surname>Jin</surname><given-names>HJ</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Positively correlated CD47 activation and autophagy in umbilical cord blood-derived mesenchymal stem cells during senescence</article-title><source>Stem Cells International</source><volume>2021</volume><elocation-id>5582792</elocation-id><pub-id pub-id-type="doi">10.1155/2021/5582792</pub-id><pub-id pub-id-type="pmid">33936211</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Knights</surname><given-names>AJ</given-names></name><name><surname>Farrell</surname><given-names>EC</given-names></name><name><surname>Ellis</surname><given-names>OM</given-names></name><name><surname>Lammlin</surname><given-names>L</given-names></name><name><surname>Junginger</surname><given-names>LM</given-names></name><name><surname>Rzeczycki</surname><given-names>PM</given-names></name><name><surname>Bergman</surname><given-names>RF</given-names></name><name><surname>Pervez</surname><given-names>R</given-names></name><name><surname>Cruz</surname><given-names>M</given-names></name><name><surname>Knight</surname><given-names>E</given-names></name><name><surname>Farmer</surname><given-names>D</given-names></name><name><surname>Samani</surname><given-names>AA</given-names></name><name><surname>Wu</surname><given-names>CL</given-names></name><name><surname>Hankenson</surname><given-names>KD</given-names></name><name><surname>Maerz</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Synovial fibroblasts assume distinct functional identities and secrete R-spondin 2 in osteoarthritis</article-title><source>Annals of the Rheumatic Diseases</source><volume>82</volume><fpage>272</fpage><lpage>282</lpage><pub-id pub-id-type="doi">10.1136/ard-2022-222773</pub-id><pub-id pub-id-type="pmid">36175067</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koh</surname><given-names>YG</given-names></name><name><surname>Kwon</surname><given-names>OR</given-names></name><name><surname>Kim</surname><given-names>YS</given-names></name><name><surname>Choi</surname><given-names>YJ</given-names></name><name><surname>Tak</surname><given-names>DH</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Adipose-derived mesenchymal stem cells with microfracture versus microfracture alone: 2-Year follow-up of a prospective randomized trial</article-title><source>Arthroscopy</source><volume>32</volume><fpage>97</fpage><lpage>109</lpage><pub-id pub-id-type="doi">10.1016/j.arthro.2015.09.010</pub-id><pub-id pub-id-type="pmid">26585585</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kojima</surname><given-names>Y</given-names></name><name><surname>Volkmer</surname><given-names>JP</given-names></name><name><surname>McKenna</surname><given-names>K</given-names></name><name><surname>Civelek</surname><given-names>M</given-names></name><name><surname>Lusis</surname><given-names>AJ</given-names></name><name><surname>Miller</surname><given-names>CL</given-names></name><name><surname>Direnzo</surname><given-names>D</given-names></name><name><surname>Nanda</surname><given-names>V</given-names></name><name><surname>Ye</surname><given-names>J</given-names></name><name><surname>Connolly</surname><given-names>AJ</given-names></name><name><surname>Schadt</surname><given-names>EE</given-names></name><name><surname>Quertermous</surname><given-names>T</given-names></name><name><surname>Betancur</surname><given-names>P</given-names></name><name><surname>Maegdefessel</surname><given-names>L</given-names></name><name><surname>Matic</surname><given-names>LP</given-names></name><name><surname>Hedin</surname><given-names>U</given-names></name><name><surname>Weissman</surname><given-names>IL</given-names></name><name><surname>Leeper</surname><given-names>NJ</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>CD47-blocking antibodies restore phagocytosis and prevent atherosclerosis</article-title><source>Nature</source><volume>536</volume><fpage>86</fpage><lpage>90</lpage><pub-id pub-id-type="doi">10.1038/nature18935</pub-id><pub-id pub-id-type="pmid">27437576</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krawetz</surname><given-names>RJ</given-names></name><name><surname>Wu</surname><given-names>YE</given-names></name><name><surname>Martin</surname><given-names>L</given-names></name><name><surname>Rattner</surname><given-names>JB</given-names></name><name><surname>Matyas</surname><given-names>JR</given-names></name><name><surname>Hart</surname><given-names>DA</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Synovial fluid progenitors expressing CD90+ from normal but not osteoarthritic joints undergo chondrogenic differentiation without micro-mass culture</article-title><source>PLOS ONE</source><volume>7</volume><elocation-id>e43616</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0043616</pub-id><pub-id pub-id-type="pmid">22952721</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krawetz</surname><given-names>RJ</given-names></name><name><surname>Affan</surname><given-names>A</given-names></name><name><surname>Leonard</surname><given-names>C</given-names></name><name><surname>Veeramreddy</surname><given-names>DN</given-names></name><name><surname>Fichadiya</surname><given-names>A</given-names></name><name><surname>Martin</surname><given-names>L</given-names></name><name><surname>Schmeling</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Synovial fluid mesenchymal progenitor cells from patients with juvenile idiopathic arthritis demonstrate limited self-renewal and chondrogenesis</article-title><source>Scientific Reports</source><volume>12</volume><elocation-id>16530</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-022-20880-7</pub-id><pub-id pub-id-type="pmid">36192450</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krawetz</surname><given-names>RJ</given-names></name><name><surname>Larijani</surname><given-names>L</given-names></name><name><surname>Corpuz</surname><given-names>JM</given-names></name><name><surname>Ninkovic</surname><given-names>N</given-names></name><name><surname>Das</surname><given-names>N</given-names></name><name><surname>Olsen</surname><given-names>A</given-names></name><name><surname>Mohtadi</surname><given-names>N</given-names></name><name><surname>Rezansoff</surname><given-names>A</given-names></name><name><surname>Dufour</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Mesenchymal progenitor cells from non-inflamed versus inflamed synovium post-ACL injury present with distinct phenotypes and cartilage regeneration capacity</article-title><source>Stem Cell Research &amp; Therapy</source><volume>14</volume><elocation-id>168</elocation-id><pub-id pub-id-type="doi">10.1186/s13287-023-03396-3</pub-id><pub-id pub-id-type="pmid">37357305</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>W-J</given-names></name><name><surname>Hah</surname><given-names>Y-S</given-names></name><name><surname>Ock</surname><given-names>S-A</given-names></name><name><surname>Lee</surname><given-names>J-H</given-names></name><name><surname>Jeon</surname><given-names>R-H</given-names></name><name><surname>Park</surname><given-names>J-S</given-names></name><name><surname>Lee</surname><given-names>S-I</given-names></name><name><surname>Rho</surname><given-names>N-Y</given-names></name><name><surname>Rho</surname><given-names>G-J</given-names></name><name><surname>Lee</surname><given-names>S-L</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Cell source-dependent in vivo immunosuppressive properties of mesenchymal stem cells derived from the bone marrow and synovial fluid of minipigs</article-title><source>Experimental Cell Research</source><volume>333</volume><fpage>273</fpage><lpage>288</lpage><pub-id pub-id-type="doi">10.1016/j.yexcr.2015.03.015</pub-id><pub-id pub-id-type="pmid">25819273</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Gui</surname><given-names>T</given-names></name><name><surname>Yao</surname><given-names>L</given-names></name><name><surname>Guo</surname><given-names>H</given-names></name><name><surname>Lin</surname><given-names>YL</given-names></name><name><surname>Lu</surname><given-names>J</given-names></name><name><surname>Duffy</surname><given-names>M</given-names></name><name><surname>Zgonis</surname><given-names>M</given-names></name><name><surname>Mauck</surname><given-names>R</given-names></name><name><surname>Dyment</surname><given-names>N</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Scanzello</surname><given-names>C</given-names></name><name><surname>Seale</surname><given-names>P</given-names></name><name><surname>Qin</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>Synovium and infrapatellar fat pad share common mesenchymal progenitors and undergo coordinated changes in osteoarthritis</article-title><source>Journal of Bone and Mineral Research</source><volume>39</volume><fpage>161</fpage><lpage>176</lpage><pub-id pub-id-type="doi">10.1093/jbmr/zjad009</pub-id><pub-id pub-id-type="pmid">38477740</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mak</surname><given-names>J</given-names></name><name><surname>Jablonski</surname><given-names>CL</given-names></name><name><surname>Leonard</surname><given-names>CA</given-names></name><name><surname>Dunn</surname><given-names>JF</given-names></name><name><surname>Raharjo</surname><given-names>E</given-names></name><name><surname>Matyas</surname><given-names>JR</given-names></name><name><surname>Biernaskie</surname><given-names>J</given-names></name><name><surname>Krawetz</surname><given-names>RJ</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Intra-articular injection of synovial mesenchymal stem cells improves cartilage repair in a mouse injury model</article-title><source>Scientific Reports</source><volume>6</volume><elocation-id>23076</elocation-id><pub-id pub-id-type="doi">10.1038/srep23076</pub-id><pub-id pub-id-type="pmid">26983696</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Masson</surname><given-names>AO</given-names></name><name><surname>Hess</surname><given-names>R</given-names></name><name><surname>O’Brien</surname><given-names>K</given-names></name><name><surname>Bertram</surname><given-names>KL</given-names></name><name><surname>Tailor</surname><given-names>P</given-names></name><name><surname>Irvine</surname><given-names>E</given-names></name><name><surname>Ren</surname><given-names>G</given-names></name><name><surname>Krawetz</surname><given-names>RJ</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Increased levels of p21((CIP1/WAF1)) correlate with decreased chondrogenic differentiation potential in synovial membrane progenitor cells</article-title><source>Mechanisms of Ageing and Development</source><volume>149</volume><fpage>31</fpage><lpage>40</lpage><pub-id pub-id-type="doi">10.1016/j.mad.2015.05.005</pub-id><pub-id pub-id-type="pmid">25987237</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Masson</surname><given-names>AO</given-names></name><name><surname>Krawetz</surname><given-names>RJ</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Understanding cartilage protection in OA and injury: a spectrum of possibilities</article-title><source>BMC Musculoskeletal Disorders</source><volume>21</volume><elocation-id>432</elocation-id><pub-id pub-id-type="doi">10.1186/s12891-020-03363-6</pub-id><pub-id pub-id-type="pmid">32620156</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maute</surname><given-names>R</given-names></name><name><surname>Xu</surname><given-names>J</given-names></name><name><surname>Weissman</surname><given-names>IL</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>CD47–SIRPα-targeted therapeutics: status and prospects</article-title><source>Immuno-Oncology and Technology</source><volume>13</volume><elocation-id>100070</elocation-id><pub-id pub-id-type="doi">10.1016/j.iotech.2022.100070</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mautner</surname><given-names>K</given-names></name><name><surname>Gottschalk</surname><given-names>M</given-names></name><name><surname>Boden</surname><given-names>SD</given-names></name><name><surname>Akard</surname><given-names>A</given-names></name><name><surname>Bae</surname><given-names>WC</given-names></name><name><surname>Black</surname><given-names>L</given-names></name><name><surname>Boggess</surname><given-names>B</given-names></name><name><surname>Chatterjee</surname><given-names>P</given-names></name><name><surname>Chung</surname><given-names>CB</given-names></name><name><surname>Easley</surname><given-names>KA</given-names></name><name><surname>Gibson</surname><given-names>G</given-names></name><name><surname>Hackel</surname><given-names>J</given-names></name><name><surname>Jensen</surname><given-names>K</given-names></name><name><surname>Kippner</surname><given-names>L</given-names></name><name><surname>Kurtenbach</surname><given-names>C</given-names></name><name><surname>Kurtzberg</surname><given-names>J</given-names></name><name><surname>Mason</surname><given-names>RA</given-names></name><name><surname>Noonan</surname><given-names>B</given-names></name><name><surname>Roy</surname><given-names>K</given-names></name><name><surname>Valentine</surname><given-names>V</given-names></name><name><surname>Yeago</surname><given-names>C</given-names></name><name><surname>Drissi</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Cell-based versus corticosteroid injections for knee pain in osteoarthritis: a randomized phase 3 trial</article-title><source>Nature Medicine</source><volume>29</volume><fpage>3120</fpage><lpage>3126</lpage><pub-id pub-id-type="doi">10.1038/s41591-023-02632-w</pub-id><pub-id pub-id-type="pmid">37919438</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miller</surname><given-names>RE</given-names></name><name><surname>Tran</surname><given-names>PB</given-names></name><name><surname>Das</surname><given-names>R</given-names></name><name><surname>Ghoreishi-Haack</surname><given-names>N</given-names></name><name><surname>Ren</surname><given-names>D</given-names></name><name><surname>Miller</surname><given-names>RJ</given-names></name><name><surname>Malfait</surname><given-names>AM</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>CCR2 chemokine receptor signaling mediates pain in experimental osteoarthritis</article-title><source>PNAS</source><volume>109</volume><fpage>20602</fpage><lpage>20607</lpage><pub-id pub-id-type="doi">10.1073/pnas.1209294110</pub-id><pub-id pub-id-type="pmid">23185004</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mora</surname><given-names>JC</given-names></name><name><surname>Przkora</surname><given-names>R</given-names></name><name><surname>Cruz-Almeida</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Knee osteoarthritis: pathophysiology and current treatment modalities</article-title><source>Journal of Pain Research</source><volume>11</volume><fpage>2189</fpage><lpage>2196</lpage><pub-id pub-id-type="doi">10.2147/JPR.S154002</pub-id><pub-id pub-id-type="pmid">30323653</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ni</surname><given-names>Z</given-names></name><name><surname>Zhou</surname><given-names>S</given-names></name><name><surname>Li</surname><given-names>S</given-names></name><name><surname>Kuang</surname><given-names>L</given-names></name><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Luo</surname><given-names>X</given-names></name><name><surname>Ouyang</surname><given-names>J</given-names></name><name><surname>He</surname><given-names>M</given-names></name><name><surname>Du</surname><given-names>X</given-names></name><name><surname>Chen</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Exosomes: roles and therapeutic potential in osteoarthritis</article-title><source>Bone Research</source><volume>8</volume><elocation-id>25</elocation-id><pub-id pub-id-type="doi">10.1038/s41413-020-0100-9</pub-id><pub-id pub-id-type="pmid">32596023</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nishimura</surname><given-names>K</given-names></name><name><surname>Solchaga</surname><given-names>LA</given-names></name><name><surname>Caplan</surname><given-names>AI</given-names></name><name><surname>Yoo</surname><given-names>JU</given-names></name><name><surname>Goldberg</surname><given-names>VM</given-names></name><name><surname>Johnstone</surname><given-names>B</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>Chondroprogenitor cells of synovial tissue</article-title><source>Arthritis and Rheumatism</source><volume>42</volume><fpage>2631</fpage><lpage>2637</lpage><pub-id pub-id-type="doi">10.1002/1529-0131(199912)42:123.0.CO;2-H</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oldenborg</surname><given-names>P-A</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>CD47: a cell surface glycoprotein which regulates multiple functions of hematopoietic cells in health and disease</article-title><source>ISRN Hematology</source><volume>2013</volume><elocation-id>614619</elocation-id><pub-id pub-id-type="doi">10.1155/2013/614619</pub-id><pub-id pub-id-type="pmid">23401787</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Palazzo</surname><given-names>C</given-names></name><name><surname>Ravaud</surname><given-names>JF</given-names></name><name><surname>Papelard</surname><given-names>A</given-names></name><name><surname>Ravaud</surname><given-names>P</given-names></name><name><surname>Poiraudeau</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>The burden of musculoskeletal conditions</article-title><source>PLOS ONE</source><volume>9</volume><elocation-id>e90633</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0090633</pub-id><pub-id pub-id-type="pmid">24595187</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peters</surname><given-names>H</given-names></name><name><surname>Potla</surname><given-names>P</given-names></name><name><surname>Rockel</surname><given-names>JS</given-names></name><name><surname>Tockovska</surname><given-names>T</given-names></name><name><surname>Pastrello</surname><given-names>C</given-names></name><name><surname>Jurisica</surname><given-names>I</given-names></name><name><surname>Delos Santos</surname><given-names>K</given-names></name><name><surname>Vohra</surname><given-names>S</given-names></name><name><surname>Fine</surname><given-names>N</given-names></name><name><surname>Lively</surname><given-names>S</given-names></name><name><surname>Perry</surname><given-names>K</given-names></name><name><surname>Looby</surname><given-names>N</given-names></name><name><surname>Li</surname><given-names>SH</given-names></name><name><surname>Chandran</surname><given-names>V</given-names></name><name><surname>Hueniken</surname><given-names>K</given-names></name><name><surname>Kaur</surname><given-names>P</given-names></name><name><surname>Perruccio</surname><given-names>AV</given-names></name><name><surname>Mahomed</surname><given-names>NN</given-names></name><name><surname>Rampersaud</surname><given-names>R</given-names></name><name><surname>Syed</surname><given-names>K</given-names></name><name><surname>Gracey</surname><given-names>E</given-names></name><name><surname>Krawetz</surname><given-names>R</given-names></name><name><surname>Buechler</surname><given-names>MB</given-names></name><name><surname>Gandhi</surname><given-names>R</given-names></name><name><surname>Kapoor</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2025">2025</year><article-title>Cell and transcriptomic diversity of infrapatellar fat pad during knee osteoarthritis</article-title><source>Annals of the Rheumatic Diseases</source><volume>84</volume><fpage>351</fpage><lpage>367</lpage><pub-id pub-id-type="doi">10.1136/ard-2024-225928</pub-id><pub-id pub-id-type="pmid">39919907</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Phinney</surname><given-names>DG</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Functional heterogeneity of mesenchymal stem cells: implications for cell therapy</article-title><source>Journal of Cellular Biochemistry</source><volume>113</volume><fpage>2806</fpage><lpage>2812</lpage><pub-id pub-id-type="doi">10.1002/jcb.24166</pub-id><pub-id pub-id-type="pmid">22511358</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Raghu</surname><given-names>H</given-names></name><name><surname>Lepus</surname><given-names>CM</given-names></name><name><surname>Wang</surname><given-names>Q</given-names></name><name><surname>Wong</surname><given-names>HH</given-names></name><name><surname>Lingampalli</surname><given-names>N</given-names></name><name><surname>Oliviero</surname><given-names>F</given-names></name><name><surname>Punzi</surname><given-names>L</given-names></name><name><surname>Giori</surname><given-names>NJ</given-names></name><name><surname>Goodman</surname><given-names>SB</given-names></name><name><surname>Chu</surname><given-names>CR</given-names></name><name><surname>Sokolove</surname><given-names>JB</given-names></name><name><surname>Robinson</surname><given-names>WH</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>CCL2/CCR2, but not CCL5/CCR5, mediates monocyte recruitment, inflammation and cartilage destruction in osteoarthritis</article-title><source>Annals of the Rheumatic Diseases</source><volume>76</volume><fpage>914</fpage><lpage>922</lpage><pub-id pub-id-type="doi">10.1136/annrheumdis-2016-210426</pub-id><pub-id pub-id-type="pmid">27965260</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Russell</surname><given-names>KC</given-names></name><name><surname>Phinney</surname><given-names>DG</given-names></name><name><surname>Lacey</surname><given-names>MR</given-names></name><name><surname>Barrilleaux</surname><given-names>BL</given-names></name><name><surname>Meyertholen</surname><given-names>KE</given-names></name><name><surname>O’Connor</surname><given-names>KC</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>In vitro high-capacity assay to quantify the clonal heterogeneity in trilineage potential of mesenchymal stem cells reveals a complex hierarchy of lineage commitment</article-title><source>Stem Cells</source><volume>28</volume><fpage>788</fpage><lpage>798</lpage><pub-id pub-id-type="doi">10.1002/stem.312</pub-id><pub-id pub-id-type="pmid">20127798</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sakaguchi</surname><given-names>Y</given-names></name><name><surname>Sekiya</surname><given-names>I</given-names></name><name><surname>Yagishita</surname><given-names>K</given-names></name><name><surname>Muneta</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Comparison of human stem cells derived from various mesenchymal tissues: superiority of synovium as a cell source</article-title><source>Arthritis and Rheumatism</source><volume>52</volume><fpage>2521</fpage><lpage>2529</lpage><pub-id pub-id-type="doi">10.1002/art.21212</pub-id><pub-id pub-id-type="pmid">16052568</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Salmon</surname><given-names>JH</given-names></name><name><surname>Rat</surname><given-names>AC</given-names></name><name><surname>Sellam</surname><given-names>J</given-names></name><name><surname>Michel</surname><given-names>M</given-names></name><name><surname>Eschard</surname><given-names>JP</given-names></name><name><surname>Guillemin</surname><given-names>F</given-names></name><name><surname>Jolly</surname><given-names>D</given-names></name><name><surname>Fautrel</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Economic impact of lower-limb osteoarthritis worldwide: a systematic review of cost-of-illness studies</article-title><source>Osteoarthritis and Cartilage</source><volume>24</volume><fpage>1500</fpage><lpage>1508</lpage><pub-id pub-id-type="doi">10.1016/j.joca.2016.03.012</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Satué</surname><given-names>M</given-names></name><name><surname>Schüler</surname><given-names>C</given-names></name><name><surname>Ginner</surname><given-names>N</given-names></name><name><surname>Erben</surname><given-names>RG</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Intra-articularly injected mesenchymal stem cells promote cartilage regeneration, but do not permanently engraft in distant organs</article-title><source>Scientific Reports</source><volume>9</volume><elocation-id>10153</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-019-46554-5</pub-id><pub-id pub-id-type="pmid">31300685</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sekiya</surname><given-names>I</given-names></name><name><surname>Ojima</surname><given-names>M</given-names></name><name><surname>Suzuki</surname><given-names>S</given-names></name><name><surname>Yamaga</surname><given-names>M</given-names></name><name><surname>Horie</surname><given-names>M</given-names></name><name><surname>Koga</surname><given-names>H</given-names></name><name><surname>Tsuji</surname><given-names>K</given-names></name><name><surname>Miyaguchi</surname><given-names>K</given-names></name><name><surname>Ogishima</surname><given-names>S</given-names></name><name><surname>Tanaka</surname><given-names>H</given-names></name><name><surname>Muneta</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Human mesenchymal stem cells in synovial fluid increase in the knee with degenerated cartilage and osteoarthritis</article-title><source>Journal of Orthopaedic Research</source><volume>30</volume><fpage>943</fpage><lpage>949</lpage><pub-id pub-id-type="doi">10.1002/jor.22029</pub-id><pub-id pub-id-type="pmid">22147634</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sekiya</surname><given-names>I</given-names></name><name><surname>Katano</surname><given-names>H</given-names></name><name><surname>Ozeki</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Characteristics of MSCs in synovial fluid and mode of action of intra-articular injections of synovial MSCs in knee osteoarthritis</article-title><source>International Journal of Molecular Sciences</source><volume>22</volume><elocation-id>2838</elocation-id><pub-id pub-id-type="doi">10.3390/ijms22062838</pub-id><pub-id pub-id-type="pmid">33799588</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Soland</surname><given-names>MA</given-names></name><name><surname>Bego</surname><given-names>M</given-names></name><name><surname>Colletti</surname><given-names>E</given-names></name><name><surname>Zanjani</surname><given-names>ED</given-names></name><name><surname>St Jeor</surname><given-names>S</given-names></name><name><surname>Porada</surname><given-names>CD</given-names></name><name><surname>Almeida-Porada</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Mesenchymal stem cells engineered to inhibit complement-mediated damage</article-title><source>PLOS ONE</source><volume>8</volume><elocation-id>e60461</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0060461</pub-id><pub-id pub-id-type="pmid">23555976</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tang</surname><given-names>S</given-names></name><name><surname>Yao</surname><given-names>L</given-names></name><name><surname>Ruan</surname><given-names>J</given-names></name><name><surname>Kang</surname><given-names>J</given-names></name><name><surname>Cao</surname><given-names>Y</given-names></name><name><surname>Nie</surname><given-names>X</given-names></name><name><surname>Lan</surname><given-names>W</given-names></name><name><surname>Zhu</surname><given-names>Z</given-names></name><name><surname>Han</surname><given-names>W</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Tian</surname><given-names>J</given-names></name><name><surname>Seale</surname><given-names>P</given-names></name><name><surname>Qin</surname><given-names>L</given-names></name><name><surname>Ding</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>Single-cell atlas of human infrapatellar fat pad and synovium implicates APOE signaling in osteoarthritis pathology</article-title><source>Science Translational Medicine</source><volume>16</volume><fpage>232</fpage><lpage>252</lpage><pub-id pub-id-type="doi">10.1126/scitranslmed.adf4590</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zheng</surname><given-names>L</given-names></name><name><surname>Gu</surname><given-names>M</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Hu</surname><given-names>X</given-names></name><name><surname>Chen</surname><given-names>C</given-names></name><name><surname>Kang</surname><given-names>Y</given-names></name><name><surname>Pan</surname><given-names>B</given-names></name><name><surname>Chen</surname><given-names>W</given-names></name><name><surname>Xian</surname><given-names>G</given-names></name><name><surname>Wu</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>C</given-names></name><name><surname>Wang</surname><given-names>C</given-names></name><name><surname>Li</surname><given-names>Z</given-names></name><name><surname>Guan</surname><given-names>M</given-names></name><name><surname>Zhou</surname><given-names>G</given-names></name><name><surname>Mobasheri</surname><given-names>A</given-names></name><name><surname>Song</surname><given-names>W</given-names></name><name><surname>Peng</surname><given-names>S</given-names></name><name><surname>Sheng</surname><given-names>P</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name></person-group><year iso-8601-date="2025">2025</year><article-title>ITGA5<sup>+</sup> synovial fibroblasts orchestrate proinflammatory niche formation by remodelling the local immune microenvironment in rheumatoid arthritis</article-title><source>Annals of the Rheumatic Diseases</source><volume>84</volume><fpage>232</fpage><lpage>252</lpage><pub-id pub-id-type="doi">10.1136/ard-2024-225778</pub-id><pub-id pub-id-type="pmid">39919897</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>W</given-names></name><name><surname>Lin</surname><given-names>J</given-names></name><name><surname>Zhao</surname><given-names>K</given-names></name><name><surname>Jin</surname><given-names>K</given-names></name><name><surname>He</surname><given-names>Q</given-names></name><name><surname>Hu</surname><given-names>Y</given-names></name><name><surname>Feng</surname><given-names>G</given-names></name><name><surname>Cai</surname><given-names>Y</given-names></name><name><surname>Xia</surname><given-names>C</given-names></name><name><surname>Liu</surname><given-names>H</given-names></name><name><surname>Shen</surname><given-names>W</given-names></name><name><surname>Hu</surname><given-names>X</given-names></name><name><surname>Ouyang</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Single-cell profiles and clinically useful properties of human mesenchymal stem cells of adipose and bone marrow origin</article-title><source>The American Journal of Sports Medicine</source><volume>47</volume><fpage>1722</fpage><lpage>1733</lpage><pub-id pub-id-type="doi">10.1177/0363546519848678</pub-id><pub-id pub-id-type="pmid">31100005</pub-id></element-citation></ref></ref-list></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.103332.3.sa0</article-id><title-group><article-title>eLife Assessment</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Radisic</surname><given-names>Milica</given-names></name><role specific-use="editor">Reviewing Editor</role><aff><institution>University of Toronto</institution><country>Canada</country></aff></contrib></contrib-group><kwd-group kwd-group-type="evidence-strength"><kwd>Convincing</kwd></kwd-group><kwd-group kwd-group-type="claim-importance"><kwd>Important</kwd></kwd-group></front-stub><body><p>This <bold>important</bold> study characterized and identified clonal MSC populations from human synovium. The authors provide <bold>convincing</bold> evidence that clonal MSC populations can be isolated and expanded from both normal and osteoarthritic synovium and that CD47 represents a potential marker for improved chondrogenic potential of MSC sub-populations. These findings could provide new avenues for osteoarthritis treatment in the future and deeper mechanistic understanding of the factors involved in the repair.</p></body></sub-article><sub-article article-type="referee-report" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.103332.3.sa1</article-id><title-group><article-title>Reviewer #1 (Public review):</article-title></title-group><contrib-group><contrib contrib-type="author"><anonymous/><role specific-use="referee">Reviewer</role></contrib></contrib-group></front-stub><body><p>Summary:</p><p>This work by Al-Jezani et al. focused on characterizing clonally derived MSC populations from the synovium of normal and osteoarthritis (OA) patients. This included characterizing the cell surface marker expression in situ (at time of isolation), as well as after in vitro expansion. The group also tried to correlate marker expression with trilineage differential potential. They also tested the ability of the different sub-populations for their efficacy in repairing cartilage in a rat model of OA. The main finding of the study is that CD47hi MSCs may have a greater capacity to repair cartilage than CD47lo MSCs, suggesting that CD47 may be a novel marker of human MSCs that have enhanced chondrogenic potential.</p><p>Strengths:</p><p>Studies on cell characterization of the different clonal populations isolated indicate that the MSC are heterogenous and traditional cell surface markers for MSCs do not accurately predict the differentiation potential of MSCs. While this has been previously established in the field of MSC therapy, the authors did attempt to characterize clones derived from single cells, as well as evaluate the marker profile at the time of isolation. While the outcome of heterogeneity is not surprising, the methods used to isolate and characterze the cells were well developed. The interesting finding of the study is the identification of CD47 as a potential MSC marker that could be related to chondrogenic potential. The authors suggest that MSCs with high CD47 repaired cartilage more effectively than MSC with low CD47 in a rat OA model.</p><p>Comments on revisions:</p><p>Thank you for addressing the comments from the first review. No additional revisions.</p></body></sub-article><sub-article article-type="referee-report" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.103332.3.sa2</article-id><title-group><article-title>Reviewer #2 (Public review):</article-title></title-group><contrib-group><contrib contrib-type="author"><anonymous/><role specific-use="referee">Reviewer</role></contrib></contrib-group></front-stub><body><p>Summary:</p><p>This is a compelling study that systematically characterized and identified clonal MSC populations derived from normal and osteoarthritis human synovium. There is immense growth in the focus on synovial-derived progenitors in the context of both disease mechanisms and potential treatment approaches, and the authors sought to understand the regenerative potential of synovial-derived MSCs.</p><p>Strengths:</p><p>This study has multiple strengths. MSC cultures were established from an impressive number of human subjects, and rigorous cell surface protein analyses were conducted, at both pre-culture and post-culture timepoints. In vivo experiments using a rat DMM model showed beneficial therapeutic effects of MSCs vs non-MSCs, with compelling data demonstrating that only &quot;real&quot; MSC clones incorporate into cartilage repair tissue and express Prg4. Proteomics analysis was performed to characterize non-MSC vs MSC cultures, and high CD47 expression was identified as a marker for MSC. Injection of CD47-Hi vs CD47-Low cells in the same rat DMM model also demonstrated beneficial effects, albeit only based on histology. A major strength of these studies is the direct translational opportunity for novel MSC-based therapeutic interventions, with high potential for a &quot;personalized medicine&quot; approach.</p><p>Weaknesses:</p><p>Weaknesses of this study include the rather cursory assessment of the OA phenotype in the rat model, confined entirely to histology (i.e. no microCT, no pain/behavioral assessments, no molecular readouts). This is relevant given the mixed results in therapeutic experiments demonstrating lower OA scores, but not lower inflammation scores, in CD47-Hi-treated rats. Thus, future work should focus on characterizing the therapeutic mechanism further given the clinical relevant of inflammation and pain in OA. It is somewhat unclear how the authors converged on CD47 vs other factors, but despite its somewhat broad profile, it was shown to be a useful marker to differentiate functional effects of MSCs. Additional work is needed to understand whether MSCs also engraft in ectopic cartilage (in the context of osteophyte/chondrophyte formation) or whether their effects are limited to articular cartilage. Despite these areas for improvement, this is a strong paper with a high degree of rigor, and the results are compelling, timely, and important.</p><p>Overall, the authors achieved their aims, and the results support not just the therapeutic value of clonally-isolated synovial MSCs but also the immense heterogeneity in stromal cell populations (containing true MSCs and non-MSCs) that must be investigated further. Of note, the authors employed the ISCT criteria to characterize MSCs, with mixed results in pre-culture and post-culture assessments. This work is likely to have a long-term impact on methodologies used to culture and study MSCs, in addition to advancing the field's knowledge about how synovial-derived progenitors contribute to cartilage repair in vivo.</p><p>Comments on revisions:</p><p>I commend the authors for a good revision. While the revision primarily entailed re-analysis or additional analysis of existing data, as well as text-based changes, it improved the clarity and completeness of the manuscript.</p><p>I do encourage the authors to expand their phenotyping assessments in future studies given that the interaction between structural disease, inflammation, and pain is complex, and our understanding of how the two interact and affect each other is evolving. There are multiple recent publications that show that a therapeutic or knock-out is protective against cartilage damage but doesn't alleviate pain, or vice versa. Thus, as a field, understanding which therapies target which pathological manifestations is an important next step to advance treatments. I also look forward to the follow-up studies on the MSC's role in ectopic cartilage.</p></body></sub-article><sub-article article-type="author-comment" id="sa3"><front-stub><article-id pub-id-type="doi">10.7554/eLife.103332.3.sa3</article-id><title-group><article-title>Author response</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Al-Jezani</surname><given-names>Nedaa</given-names></name><role specific-use="author">Author</role><aff><institution>University of Calgary</institution><addr-line><named-content content-type="city">Calgary</named-content></addr-line><country>Canada</country></aff></contrib><contrib contrib-type="author"><name><surname>Affan</surname><given-names>Asmaa</given-names></name><role specific-use="author">Author</role><aff><institution>University of Calgary</institution><addr-line><named-content content-type="city">Calgary</named-content></addr-line><country>Canada</country></aff></contrib><contrib contrib-type="author"><name><surname>Leonard</surname><given-names>Catherine</given-names></name><role specific-use="author">Author</role><aff><institution>University of Calgary</institution><addr-line><named-content content-type="city">Calgary</named-content></addr-line><country>Canada</country></aff></contrib><contrib contrib-type="author"><name><surname>Das</surname><given-names>Nabangshu</given-names></name><role specific-use="author">Author</role><aff><institution>Cell Biology and Anatomy, Cumming School of Medicine, University of Calgary, 3330 Hospital Drive NW, Calgary, Alberta T2N4N1, Canada.</institution><addr-line><named-content content-type="city">Alberta</named-content></addr-line><country>Canada</country></aff></contrib><contrib contrib-type="author"><name><surname>Almeida</surname><given-names>Luiz Gustavo</given-names></name><role specific-use="author">Author</role><aff><institution>University of Calgary</institution><addr-line><named-content content-type="city">Calgary</named-content></addr-line><country>Canada</country></aff></contrib><contrib contrib-type="author"><name><surname>Young</surname><given-names>Daniel</given-names></name><role specific-use="author">Author</role><aff><institution>University of Calgary</institution><addr-line><named-content content-type="city">Calgary</named-content></addr-line><country>Canada</country></aff></contrib><contrib contrib-type="author"><name><surname>Masson</surname><given-names>Anand O</given-names></name><role specific-use="author">Author</role><aff><institution>University of Calgary</institution><addr-line><named-content content-type="city">Calgary</named-content></addr-line><country>Canada</country></aff></contrib><contrib contrib-type="author"><name><surname>Dufour</surname><given-names>Antoine</given-names></name><role specific-use="author">Author</role><aff><institution>University of Calgary</institution><addr-line><named-content content-type="city">Calgary</named-content></addr-line><country>Canada</country></aff></contrib><contrib contrib-type="author"><name><surname>Salo</surname><given-names>Paul</given-names></name><role specific-use="author">Author</role><aff><institution>University of Calgary</institution><addr-line><named-content content-type="city">Calgary</named-content></addr-line><country>Canada</country></aff></contrib><contrib contrib-type="author"><name><surname>Railton</surname><given-names>Pam</given-names></name><role specific-use="author">Author</role><aff><institution>University of Calgary</institution><addr-line><named-content content-type="city">Calgary</named-content></addr-line><country>Canada</country></aff></contrib><contrib contrib-type="author"><name><surname>Powell</surname><given-names>James N</given-names></name><role specific-use="author">Author</role><aff><institution>University of Calgary</institution><addr-line><named-content content-type="city">Calgary</named-content></addr-line><country>Canada</country></aff></contrib><contrib contrib-type="author"><name><surname>Krawetz</surname><given-names>Roman J</given-names></name><role specific-use="author">Author</role><aff><institution>University of Calgary</institution><addr-line><named-content content-type="city">Calgary</named-content></addr-line><country>Canada</country></aff></contrib></contrib-group></front-stub><body><p>The following is the authors’ response to the original reviews.</p><disp-quote content-type="editor-comment"><p><bold>Public Reviews:</bold></p><p><bold>Reviewer #1 (Public review):</bold></p><p>Summary:</p><p>This work by Al-Jezani et al. focused on characterizing clonally derived MSC populations from the synovium of normal and osteoarthritis (OA) patients. This included characterizing the cell surface marker expression in situ (at time of isolation), as well as after in vitro expansion. The group also tried to correlate marker expression with trilineage differential potential. They also tested the ability of the different subpopulations for their efficacy in repairing cartilage in a rat model of OA. The main finding of the study is that CD47hi MSCs may have a greater capacity to repair cartilage than CD47lo MSCs, suggesting that CD47 may be a novel marker of human MSCs that have enhanced chondrogenic potential.</p><p>Strengths:</p><p>Studies on cell characterization of the different clonal populations isolated indicate that the MSC are heterogenous and traditional cell surface markers for MSCs do not accurately predict the differentiation potential of MSCs. While this has been previously established in the field of MSC therapy, the authors did attempt to characterize clones derived from single cells, as well as evaluate the marker profile at the time of isolation. While the outcome of heterogeneity is not surprising, the methods used to isolate and characterize the cells were well developed. The interesting finding of the study is the identification of CD47 as a potential MSC marker that could be related to chondrogenic potential. The authors suggest that MSCs with high CD47 repaired cartilage more effectively than MSC with low CD47 in a rat OA model.</p><p>Weaknesses:</p><p>While the identification of CD47 as a novel MSC marker could be important to the field of cell therapy and cartilage regeneration, there was a lack of robust data to support the correlation of CD47 expression to chondrogenesis. The authors indicated that the proteomics suggested that the MSC subtype expressed significantly more CD47 than the non-MSC subtype. However, it was difficult to appreciate where this was shown. It would be helpful to clearly identify where in the figure this is shown, especially since it is the key result of the study. The authors were able to isolate CD47hi and CD47 low cells. While this is exciting, it was unclear how many cells could be isolated and whether they needed to be expanded before being used in vivo. Additional details for the CD47 studies would have strengthened the paper. Furthermore, the CD47hi cells were not thoroughly characterized in vitro, particularly for in vitro chondrogenesis. More importantly, the in vivo study where the CD47hi and CD47lo MSCs were injected into a rat model of OA lacked experimental details regarding how many cells were injected and how they were labeled. No representative histology was presented and there did not seem to be a statistically significant difference between the OARSI score of the saline injected and MSC injected groups. The repair tissue was stained for Sox9 expression, which is an important marker of chondrogenesis but does not show production of cartilage. Expression of Collagen Type II would be needed to more robustly claim that CD47 is a marker of MSCs with enhanced repair potential.</p><p><bold>Reviewer #2 (Public review):</bold></p><p>Summary:</p><p>This is a compelling study that systematically characterized and identified clonal MSC populations derived from normal and osteoarthritis human synovium. There is immense growth in the focus on synovial-derived progenitors in the context of both disease mechanisms and potential treatment approaches, and the authors sought to understand the regenerative potential of synovial-derived MSCs.</p><p>Strengths:</p><p>This study has multiple strengths. MSC cultures were established from an impressive number of human subjects, and rigorous cell surface protein analyses were conducted, at both pre-culture and post-culture timepoints. In vivo experiments using a rat DMM model showed beneficial therapeutic effects of MSCs vs non-MSCs, with compelling data demonstrating that only &quot;real&quot; MSC clones incorporate into cartilage repair tissue and express Prg4. Proteomics analysis was performed to characterize non-MSC vs MSC cultures, and high CD47 expression was identified as a marker for MSC. Injection of CD47-Hi vs CD47-Low cells in the same rat DMM model also demonstrated beneficial effects, albeit only based on histology. A major strength of these studies is the direct translational opportunity for novel MSC-based therapeutic interventions, with high potential for a &quot;personalized medicine&quot; approach.</p><p>Weaknesses:</p><p>Weaknesses of this study include the rather cursory assessment of the OA phenotype in the rat model, confined entirely to histology (i.e. no microCT, no pain/behavioral assessments, no molecular readouts). It is somewhat unclear how the authors converged on CD47 vs the other factors identified in the proteomics screen, and additional information is needed to understand whether true MSCs only engraft in articular cartilage or also in ectopic cartilage (in the context of osteophyte/chondrophyte formation). Some additional discussion and potential follow-up analyses focused on other cell surface markers recently described to identify synovial progenitors is also warranted. A conceptual weakness is the lack of discussion or consideration of the multiple recent studies demonstrating that DPP4+ PI16+ CD34+ stromal cells (i.e. the &quot;universal fibroblasts&quot;) act as progenitors in all mesenchymal tissues, and their involvement in the joint is actively being investigated. Thus, it seems important to understand how the MSCs of the present study are related to these DPP4+ progenitors. Despite these areas for improvement, this is a strong paper with a high degree of rigor, and the results are compelling, timely, and important.</p><p>Overall, the authors achieved their aims, and the results support not just the therapeutic value of clonally-isolated synovial MSCs but also the immense heterogeneity in stromal cell populations (containing true MSCs and non-MSCs) that must be investigated further. Of note, the authors employed the ISCT criteria to characterize MSCs, with mixed results in pre-culture and post-culture assessments. This work is likely to have a longterm impact on methodologies used to culture and study MSCs, in addition to advancing the field's knowledge about how synovial-derived progenitors contribute to cartilage repair in vivo.</p><p><bold>Recommendations for the authors:</bold></p><p><bold>Reviewer #1 (Recommendations for the authors):</bold></p><p>In all figures, it would be beneficial to report the sample number used for the data reported. It is difficult to appreciate the statistical analysis without that information.</p></disp-quote><p>Understood, the sample number and replicates have been added to each figure legend.</p><disp-quote content-type="editor-comment"><p>Please check that Table S7 is part of the manuscript. It could not be found.</p></disp-quote><p>It was added as an additional excel file since it was too large to fit in the word document.</p><disp-quote content-type="editor-comment"><p>Lines 377-379 (Figure 2E): the authors write that rats receiving MSCs had a significantly lower OARSI and Krenn score vs. rats injected with non-MSCs. However, none of the bars indicating statistical significance run between these two groups. Please verify the text and figure.</p></disp-quote><p>This has been corrected</p><disp-quote content-type="editor-comment"><p>The details surrounding the labeling of the cells with tdTomato were not presented in the methods.</p></disp-quote><p>This has been added to the methods</p><disp-quote content-type="editor-comment"><p>The fluorescent antibodies used should be listed and more details provided in the methods rather than a general statement that fluorescent antibodies were used.</p></disp-quote><p>Our apologies, the clones and companies have been added.</p><disp-quote content-type="editor-comment"><p>Additional information on the CD47 experiments (# cells, # animals) would have strengthened the study.</p></disp-quote><p>This has been added to the methods and figure legend.</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #2 (Recommendations for the authors):</bold></p><p>My comments span minor corrections, requests for additional analyses, some suggestions for additional experiments, and requests for additional discussion of recent important studies.</p><p>Introduction:</p><p>The introduction is thorough and well-written. I recommend a brief discussion about the emerging evidence demonstrating that DPP4+ PI16+ CD34+ synovial cells, i.e. the &quot;universal fibroblasts&quot;, act as stromal progenitors in development, homeostasis, and disease. Relevant osteoarthritis-related papers encompass human and mouse studies (PMIDs: 39375009, 38266107, 38477740, 36175067, 36414376).</p></disp-quote><p>This has been added.</p><disp-quote content-type="editor-comment"><p>Relatedly, as DPP4 is CD26 and therefore useful as a cell-surface antigen for flow cytometry, sorting, etc, it would be interesting to understand the relationship and similarities between the CD47-High cells identified in this study and the DPP4/PI16+ cells previously described. Do they overlap in phenotype/identity?</p></disp-quote><p>We have added a new flow cytometry figure for address this question.</p><disp-quote content-type="editor-comment"><p>Results:</p><p>Note type-o on Line 311: &quot;preformed&quot; instead of &quot;performed&quot;. Line 313 &quot;prolife&quot; instead of &quot;profile&quot;</p></disp-quote><p>Thank you for catching these.</p><disp-quote content-type="editor-comment"><p>The identified convergence of the cell surface marker profile of all normal and OA clones in culture is a highly intriguing result. Do the authors have stored aliquots of these cells to demonstrate whether this would also occur in soft substrate, i.e. low stiffness culture conditions? This could be done with standard dishes coated with bulk collagen or with commercially available low-stiffness dishes (1 kPa). This is relevant to multiple studies demonstrating the induction of a myofibroblast-like phenotype by stromal cells cultured on high-stiffness plastic or glass. This is also the experiment where assessment of DPP4/CD26 could be added, if possible.</p></disp-quote><p>While we agree it would be interesting to determine the mechanism by which the cells phenotypes converge, we would argue that it is outside of the scope of the current manuscript. We have instead added a sentence to the discussion.</p><disp-quote content-type="editor-comment"><p>Line 353 regarding the use of CD68 as a negative gate: can the authors pleasecomment on why they employed CD68 here and not CD45? While monocytes/macs/myeloid cells are the most abundant immune cells in synovium, CD45 would more comprehensively exclude all immune cells.</p></disp-quote><p>That is a fair point, and we really don’t have any reason to have picked CD68 over CD45. In our opinion either would be a fair negative marker to use based on the literature.</p><disp-quote content-type="editor-comment"><p>Fig 2, minor suggestion: consider adding &quot;MSC vs non-MSC&quot; on the experimental schematic to more comprehensively summarize the experiment.</p></disp-quote><p>This has been modified</p><disp-quote content-type="editor-comment"><p>Fig 2E should show all individual datapoints, not just bar graphs.</p></disp-quote><p>This has been modified</p><disp-quote content-type="editor-comment"><p>Fig 2: Given the significant reduction in Krenn score in DMM-MSC injected knees compared to DMM-saline knees, Fig 2 should also show representative images of the synovial phenotype to demonstrate which aspects of synovial pathology were mitigated. Was the effect related to lining hyperplasia, subsynovial infiltrate, fibrosis, etc? Similarly, can the authors narrate which aspects of the OARSI score drove the treatment effect (proteoglycans vs structure vs osteophytes, etc).</p></disp-quote><p>We have added a new sup figure breaking down the Krenn score as well as higher magnification images of representative synovium.</p><disp-quote content-type="editor-comment"><p>Fig 2: In the absence of microCT imaging, can the authors quantify subchondral bone morphometrics using multiple histological sections? The tibial subchondral bone in Fig 2D appears protected from sclerosis/thickening.</p></disp-quote><p>Unfortunately, this is beyond what are able to add to the manuscript.</p><disp-quote content-type="editor-comment"><p>The Fig 3 results are highly compelling and interesting. Congratulations.</p></disp-quote><p>Thank you very much.</p><disp-quote content-type="editor-comment"><p>Fig 4A: the cell highlighted in the high-mag zoom box in Fig 4A appears to be localized within the joint capsule or patellar tendon (it is unclear which anatomic region this image represents). The highly aligned nature of the tissue and cells along a fibrillar geometry indicates that this is not synovium. The interface between synovium and the tissue in question can be clearly observed in this image. Please choose an image more representative of synovium.</p></disp-quote><p>We completely agree with the reviewers assessment. However, it is the synovium that overlays this tissue (Fig 4A arrow). We are simply showing that there were very few MSCs that took up residence in the synovium or the adjacent tissues.</p><disp-quote content-type="editor-comment"><p>Fig 4C and F: please show individual data points.</p></disp-quote><p>This has been added</p><disp-quote content-type="editor-comment"><p>Fig 5D: I see DPP4 and ITGA5 were also hits in the proteomics analysis, which is intriguing. Besides my comments/suggestions regarding DPP4 above, please note this recent paper identifying a ITGA5+ synovial fibroblast subset that orchestrates pathological crosstalk with lymphocytes in RA, PMID: 39486872</p></disp-quote><p>Thank you for the information. We have added the reference in the results section.</p><disp-quote content-type="editor-comment"><p>Fig 5B-D: How did the authors converge on CD47 as the target for follow-up study? It does not appear to be a differentially-expressed protein based on the Volcano plot in Fig 5B, and it's unclear why it is a more important factor than any of the other proteins shown in the network diagram in Fig 5D, e.g. CTSL, ITGA5, DPP4. Can the authors add a quantitative plot supporting their statement &quot;the MSC sub-type expressed significantly more CD47 than the non-MSCs&quot; on Line 458?</p></disp-quote><p>We have re-written this line. It was incorrect to discuss amount of CD47. That was shown later with the flow analysis.</p><disp-quote content-type="editor-comment"><p>Fig 6D: Please show individual data points and also representative histology images to demonstrate the nature of the phenotypic effect.</p></disp-quote><p>This has been added.</p><disp-quote content-type="editor-comment"><p>Fig 6E-F: In what anatomic region are these images? Please add anatomic markers to clarify the location and allow the reader to interpret whether this is articular cartilage or ectopic cartilage</p></disp-quote><p>We have redone the figure to show the area as requested.</p><disp-quote content-type="editor-comment"><p>Relevant to this, do the authors observe this type of cellular engraftment in ectopic cartilage/osteophytes or only in articular cartilage? Understanding the contribution of these cells to the formation/remodeling of various cartilage types in the context of OA is a critical aspect of this line of investigation.</p></disp-quote><p>We didn’t see any contribution of these cells to ectopic cartilage formation and are actively working on a follow up study discussing this point specifically.</p><disp-quote content-type="editor-comment"><p>Discussion:</p><p>Besides my comments regarding DPP4 and ITGA5 above, the authors may also consider discussing PMID: 37681409 (JCI Insight 2023), which demonstrates that adult Prg4+ progenitors derived from synovium contribute to articular cartilage repair in vivo.</p></disp-quote><p>We agree that there are numerous markers we could look at in future studies and that other people in the field are actively studying.</p></body></sub-article></article>